Microneedle devices and methods, and skin disease assays
Patent Information
- Application Number
- JP2023533232
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-30
- Filing Date
- 2021-11-29
- Publication Date
- 2024-12-06
AI Technical Summary
Current treatments for autoimmune diseases like psoriasis are costly and inefficient due to genetic variability among patients, requiring a trial-and-error approach with therapeutic agents, leading to prolonged ineffective treatments and significant impact on quality of life.
A microneedle device with a specific design and nucleic acid probes is used to penetrate the skin, extract RNA, and analyze gene expression profiles to predict patient response to autoimmune treatments with high accuracy, allowing personalized treatment regimens.
The method achieves a positive predictive value of over 80% in predicting patient response to treatments like IL-17, IL-23, and TNFα-mediated therapies, optimizing treatment selection and reducing trial-and-error approaches.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 63 / 119,511, filed November 30, 2020, the contents of which are incorporated herein by reference in their entirety. [Background technology]
[0002] Nearly 4% of the world's population is affected by one of more than 80 known autoimmune diseases. In the United States alone, 24 million people suffer from autoimmune diseases. The cost of treating autoimmune diseases in the United States is estimated to be more than 100 billion US dollars per year. Autoimmune diseases can encompass a wide variety of different diseases and illnesses that can affect a single tissue or organ, or multiple tissues or organs simultaneously. Some autoimmune diseases specifically target the skin. The etiology of any particular autoimmune disease is often unknown, but an imbalance in immune regulation is often involved.
[0003] For example, psoriasis is a chronic autoimmune disease characterized by abnormal raised areas of skin.It is a chronic condition that can cause thick, scaly patches or plaques to form on the skin.It is estimated that more than 8 million people in the United States have psoriasis.Currently, there is no cure for psoriasis, but there are treatments available to control symptoms.
[0004] Microneedle devices, which include an array of relatively small structures, sometimes referred to as microneedles or micropins, can be used in connection with the delivery of therapeutic agents and other substances through the skin and other surfaces. While treatments for autoimmune diseases exist, patient responses vary. New strategies are needed to determine the likelihood that subjects with autoimmune diseases will respond to therapeutic agents.
[0005] To treat a subject's autoimmune disease, doctors may prescribe therapeutic drugs that aim to inhibit or block specific immune system biochemical pathways to manage symptoms.Unfortunately, due to the genetic diversity of subjects with autoimmune disease, a single therapeutic drug may not be the ideal candidate for two subjects with similar autoimmune diseases.This variability between subjects' genetic profiles leads to a trial-and-error methodology for prescribing therapeutic drugs, often requiring the administration of therapeutic drugs for several months, which may prove ineffective in treating a given subject.This approach is costly for insurance payers and is an ineffective way to manage autoimmune disease, which may have a substantial impact on the subject's quality of life. Summary of the Invention
[0006] An embodiment of the present disclosure provides a microneedle device comprising: 1) (i) a microneedle base substrate comprising a first base substrate surface and a second base substrate surface, the first base substrate surface and the second base substrate surface being disposed on opposite sides of the microneedle base substrate; and (ii) a microneedle region comprising a plurality of microneedles protruding from the first base substrate surface; and b) a support substrate adjacent to the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate and comprising a depth of the support substrate, wherein the depth of the support substrate is greater than the minimum distance between the first base substrate surface and the second base substrate surface.
[0007] Another embodiment provides a microneedle device comprising: 1) a microneedle region comprising a microneedle base substrate, the microneedle base substrate comprising a first base substrate surface with a plurality of microneedles protruding from the first base substrate surface, the microneedle base substrate further comprising a second base substrate surface opposite the first base substrate surface, the second base substrate surface comprising recesses aligned with at least a portion of the plurality of microneedles; and b) a support substrate adjacent to the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate.
[0008] In some embodiments, the minimum distance between the first and second base substrate surfaces of the microneedle base substrate is about 1 μm to about 500 μm less than the depth of the support substrate. In some embodiments, the minimum distance between the first and second base substrate surfaces is 150 μm to about 350 μm. In some embodiments, the ratio between (a) the minimum distance between the first and second base substrate surfaces and (b) the depth of the support substrate is at least 1:5. In some embodiments, the microneedle region includes a perimeter, and the support substrate is adjacent to at least half of the perimeter. In some embodiments, the support substrate includes a first support substrate surface proximal to the plurality of microneedles (sometimes referred to herein as the "front support substrate surface") and a second support substrate surface distal to the plurality of microneedles and opposite the first support substrate surface (sometimes referred to herein as the "rear support substrate surface"), wherein the second support substrate surface is not coplanar with the second support substrate surface distal to the plurality of microneedles. In some embodiments, the first support substrate surface is not coplanar with the surface of the support substrate. In some embodiments, the plurality of microneedles are plasma treated. In some embodiments, the plurality of probes are coupled to the microneedles of the plurality of microneedles. In some embodiments, the plurality of probes comprise a negative charge. In some embodiments, the plurality of microneedles comprise a polyolefin resin. In some embodiments, the polyolefin resin comprises one or both of Zeonor 1020R and Zeonor 690R. In some embodiments, the microneedles of the plurality of microneedles are non-dissolvable. In some embodiments, the microneedles of the plurality of microneedles are pyramidal. In some embodiments, the microneedles of the plurality of microneedles are solid. In some embodiments, the angle between the base of the microneedle and the microneedle base substrate is between about 60° and about 90°. In some embodiments, the recess aligned with at least a portion of the plurality of microneedles has a width that is greater than the width of the mechanical applicator.
[0009] Another aspect of the present disclosure provides a kit comprising a microneedle device, the microneedle device comprising: (1) a microneedle region comprising a microneedle base substrate, the microneedle base substrate comprising a first base substrate surface with a plurality of microneedles protruding from the first base substrate surface, the microneedle base substrate further comprising a second base substrate surface opposite the first base substrate surface, the second base substrate surface comprising recesses aligned with at least a portion of the plurality of microneedles; b) a support substrate adjacent to the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate; and (c) a mechanical applicator that fits within the recesses aligned with at least a portion of the plurality of microneedles.
[0010] In some embodiments, at least one of the plurality of microneedles is attached to a nucleic acid probe. In some embodiments, the nucleic acid probe comprises a homopolymer sequence. In some embodiments, the homopolymer sequence comprises thymine or uracil. In some embodiments, the nucleic acid probe comprises DNA. In some embodiments, the nucleic acid probe comprises thymine. In some embodiments, the nucleic acid probe comprises thymidine. In some embodiments, the nucleic acid probe is covalently attached to the microneedle. In some embodiments, the support substrate comprises a fiducial marker. In some embodiments, no more than three microneedles of the plurality of microneedles are less than 600 μm in length or more than 1050 μm in length.
[0011] Another aspect of the present disclosure provides a method for preparing a biological sample from a subject, the method comprising contacting the subject's skin with any of the devices described herein, applying pressure to the microneedle device so that the microneedle device penetrates the subject's skin, and allowing nucleic acids in the subject's skin to contact the microneedle device. In some embodiments, the method further comprises extracting nucleic acids, including, for example, RNA and mRNA. In some embodiments, the method further comprises converting the mRNA into cDNA. In some embodiments, the subject is human. In some embodiments, the subject has psoriasis or symptoms of psoriasis. In some embodiments, the subject has a skin disease or symptoms of a skin disease.
[0012] Another aspect of the present disclosure provides a method for preparing a biological sample from a subject, the method comprising: a) contacting the subject's skin with a microneedle device, the microneedle device comprising a plurality of nucleic acid probes attached to microneedles; b) applying pressure to the microneedle device to penetrate the subject's skin; c) penetrating the microneedle device through the subject's skin for 10 minutes or less to obtain a ribonucleic acid (RNA) sample hybridized to the nucleic acid probes, the RNA sample comprising a population of RNA fragments comprising about 700 bases or more and a population of RNA fragments comprising about 150 bases to about 200 bases, and the ratio of the population of RNA fragments comprising about 700 bases or more to the population of RNA fragments comprising about 150 bases to about 200 bases is greater than 1; and d) removing the microneedle device from the subject's skin, wherein after the microneedle device is removed from the subject's skin, the RNA sample comprises the RNA sample hybridized to the nucleic acid probes. In some embodiments, the RNA sample is substantially free of contaminants. In some embodiments, the microneedle device can penetrate the subject's skin for about 5 minutes. In some embodiments, the microneedle device penetrates the subject's skin for less than 60 minutes, less than 45 minutes, less than 40 minutes, less than 30 minutes, less than 15 minutes, less than 10 minutes, less than 5 minutes, less than 3 minutes, less than 2 minutes, or less than 1 minute. In some embodiments, the microneedle device penetrates the subject's skin for more than 30 seconds, more than 45 seconds, more than 1 minute, more than 5 minutes, more than 10 minutes, or more than 30 minutes.
[0013] Another aspect of the present disclosure includes a method of treating a subject with a skin autoimmune disease, the method comprising: a) collecting a sample containing skin-derived RNA from the subject, wherein the subject has not administered the autoimmune therapeutic agent within 7 days prior to collecting the RNA-containing sample; b) determining the expression level of at least one gene based on the RNA; c) predicting that the subject with the skin autoimmune disease will be responsive to the autoimmune therapeutic agent based on the expression level of the at least one gene with a positive predictive value of greater than 80%; and d) treating the subject with the autoimmune therapeutic agent based on the prediction of (c). In some cases, the PPV is greater than about 90%. In some cases, the PPV is greater than 95% for a cohort of more than 100 patients. In some examples, the autoimmune therapeutic agent is a biologic or comprises an antibody. In some cases, the autoimmune therapeutic agent is an IL-17-mediated treatment, an IL-23-mediated treatment, or a TNFα-mediated treatment. In some cases, the autoimmune therapeutic agent is at least one drug selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab. In some embodiments, the at least one gene comprises at least two genes, three genes, four genes, or five genes. In some embodiments, the at least one gene comprises at least two genes, three genes, four genes, five genes, six genes, seven genes, eight genes, nine genes, or ten genes from Table 6, Table 12, or Table 13. In some examples, the at least one gene comprises at least two genes that do not share a common upregulator. In some cases, the autoimmune disorder is psoriasis. In some cases, the subject has a PASI of more than 8. In some cases, the subject has a PASI of at least 75 after treating the subject with the autoimmune therapeutic agent. In some cases, the RNA includes mRNA or microRNA and is converted into cDNA, which is then sequenced using next-generation sequencing.In some cases, the step of collecting a sample comprising skin-derived RNA from the subject comprises piercing the subject's skin with a microneedle device, wherein the microneedle device comprises a microneedle conjugated to a nucleic acid probe. In some embodiments, the trained algorithm is applied to data generated by next-generation sequencing of cDNA. In some embodiments, the algorithm was trained using samples from patients administered one drug selected from the group consisting of an IL-17-mediated treatment, a TNF-α-mediated treatment, and an IL-23-mediated treatment. In some embodiments, the autoimmune therapeutic agent is an IL-17-mediated treatment, and the at least one gene comprises at least one gene not involved in an IL-17-mediated pathway. In some embodiments, the autoimmune therapeutic agent is an IL-23-mediated treatment, and the at least one gene comprises at least one gene not involved in an IL-23-mediated pathway. In some embodiments, the autoimmune therapeutic agent is a TNF-α-mediated treatment, and the at least one gene comprises at least one gene not involved in a TNF-α-mediated pathway.
[0014] Another aspect of the present disclosure includes a method for determining whether a subject's skin lesion is responsive to an autoimmune therapeutic agent, the method comprising: collecting a sample containing skin-derived RNA from the subject, wherein the subject has not administered an autoimmune therapeutic agent within seven days prior to collecting the RNA-containing sample; converting the RNA into cDNA; determining the expression of at least one gene based on the cDNA; and predicting whether the subject with the skin lesion will respond to the autoimmune therapeutic agent with a positive predictive value of greater than 80%. In some examples, the PPV is greater than about 90%. In some examples, the PPV is greater than 95% for a cohort of more than 100 patients. In some embodiments, the autoimmune therapeutic agent is a biologic or comprises an antibody. In some embodiments, the autoimmune therapeutic agent is an IL-17-mediated treatment, an IL-23-mediated treatment, or a TNFα-mediated treatment. In some embodiments, the autoimmune therapeutic agent is at least one drug selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab. In some embodiments, the autoimmune therapeutic agent is at least one drug selected from the group consisting of certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab. In some embodiments, the at least one gene comprises at least two genes, three genes, four genes, or five genes. In some embodiments, the at least one gene comprises at least two genes, three genes, four genes, five genes, six genes, seven genes, eight genes, nine genes, or ten genes from Table 6, Table 12, or Table 13. In some instances, the at least one gene comprises at least two genes that do not share a common upregulator.In some instances, the autoimmune disorder is psoriasis.In some instances, the subject has a PASI greater than 8.In some instances, the subject has a PASI of at least 75 after treating the subject with an autoimmune therapeutic agent.In some cases, the RNA includes mRNA or microRNA and is converted into cDNA, which is then sequenced using next-generation sequencing. In some cases, collecting a sample containing skin-derived RNA from a subject includes piercing the subject's skin with a microneedle device, wherein the microneedle device includes a microneedle conjugated to a nucleic acid probe. In some embodiments, the trained algorithm is applied to data generated by next-generation sequencing of the cDNA. In some embodiments, the algorithm was trained using samples from patients administered a drug selected from the group consisting of an IL-17-mediated treatment, a TNF-α-mediated treatment, and an IL-23-mediated treatment.
[0015] Another aspect of the present disclosure provides a method for determining whether a subject's skin lesions are responsive to an autoimmune disease therapeutic agent, the method comprising: penetrating the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to the microneedles; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; aligning the sequence reads with a sequence read signature associated with a positive response to the autoimmune disease therapeutic agent to obtain aligned sequence reads; and applying a trained algorithm to the aligned sequence reads, wherein the trained algorithm has a positive predictive value of greater than 80% for predicting response to the autoimmune disease therapeutic agent.
[0016] Another aspect of the present disclosure provides a method for determining whether a subject's skin lesion is responsive to an autoimmune disease therapeutic agent, the method comprising: penetrating the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to solid microneedles; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; aligning the sequence reads with a sequence read signature associated with a positive response to the autoimmune disease therapeutic agent to obtain aligned sequence reads; determining an expression level of at least one RNA molecule using the aligned sequence reads; and applying a trained algorithm to the expression level of the at least one RNA molecule, wherein the trained algorithm predicts whether the subject with the skin lesion will be responsive to an IL-17-mediated treatment, an IL-23-mediated treatment, a TNFα-mediated treatment, or any combination thereof. In some embodiments, the subject is responsive to the IL-17-mediated treatment, the IL-23-mediated treatment, and the TNFα-mediated treatment. In some embodiments, the at least one gene comprises at least two, three, four, or five genes. In some embodiments, the at least one gene comprises at least two, three, four, five, six, seven, eight, nine, or ten genes from Table 6, Table 12, or Table 13. In some examples, the at least one gene comprises at least two genes that do not share a common upregulator. In some cases, the autoimmune disorder is psoriasis. In some cases, the subject has a PASI of more than 8. In some cases, the subject has a PASI of at least 75 after treating the subject with an autoimmune therapeutic agent. In some cases, the RNA comprises mRNA or microRNA and is converted into cDNA, which is then sequenced using next-generation sequencing. In some embodiments, the recommended therapeutic agent comprises one or more autoimmune therapeutic agents for an autoimmune disease or condition.In some embodiments, the recommended treatment includes etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab, or any combination thereof.
[0017] In some embodiments, the methods described herein further include performing high-throughput sequencing on RNA biomarkers to generate one or more sequence reads for a subject, aligning the one or more sequence reads for the subject with a known signature of sequence reads, where the known signature of sequence reads is associated with a positive response to the recommended therapeutic agent, thereby obtaining aligned sequence reads, and classifying the subject as having a likelihood of a positive response to the recommended therapeutic agent by applying a trained algorithm to the aligned sequence reads, where the trained algorithm has a positive predictive value of greater than 50% for predicting a positive response to the recommended therapeutic agent. In some embodiments, the trained algorithm has a negative predictive value of greater than 50%.
[0018] Another aspect of the present disclosure provides a method for determining whether a subject with an autoimmune disorder of the skin will be responsive to an autoimmune therapeutic agent, the method comprising extracting mRNA from the skin of the subject, sequencing the mRNA from the skin of the subject, and predicting whether the subject with the autoimmune disorder will be responsive to etanercept, adalimumab, infliximab, certolizumab, secukinumab, ixekizumab, broadalumab, guselkumab, tildrakizumab, and risankizumab with a positive predictive value of greater than 80%.
[0019] Another aspect of the present disclosure provides a method of determining whether a subject's skin lesion will be responsive to IL-23-mediated treatment, the method comprising: contacting the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to solid microneedles such that the microneedle device penetrates the subject's skin; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; aligning the sequence reads with a signature of sequence reads associated with a positive response to an autoimmune disease therapeutic agent to obtain aligned sequence reads; and applying a trained algorithm to the aligned sequence reads, wherein the trained algorithm predicts whether the subject with the skin lesion will respond to IL-23-mediated treatment, and wherein the aligned sequence reads correspond to at least one gene from Table 13.
[0020] Another aspect of the present disclosure provides a method of determining whether a subject's skin lesion will respond to an IL-17-, IL-23-, or TNF-α-mediated treatment, the method comprising: contacting the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to solid microneedles such that the microneedle device penetrates the subject's skin; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; aligning the sequence reads with a signature of sequence reads associated with a positive response to an autoimmune disease therapeutic agent to obtain aligned sequence reads; and applying a trained algorithm to the aligned sequence reads, wherein the trained algorithm predicts whether the subject with the skin lesion will respond to the IL-17-, TNF-α-, or IL-23-mediated treatment, and wherein the aligned sequence reads correspond to at least one gene from Table 6, 12, or 13. In some embodiments, the subject is treated with an IL-17-mediated treatment and the aligned sequence reads correspond to at least one gene, two genes, three genes, four genes, five genes, or six genes from Table 12. In some embodiments, the subject is treated with a TNF-α-mediated treatment and the aligned sequence reads correspond to at least one gene, two genes, three genes, four genes, five genes, or six genes from Table 6. In some embodiments, the subject is treated with an IL-23-mediated treatment and the aligned sequence reads correspond to at least one gene, two genes, three genes, four genes, five genes, or six genes from Table 13.
[0021] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CNFN, CTSC, GBAP1, CRABP2, PCDH7, PPIG, RAB31, C3, and EGR. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CNFN, CTSC, GBAP1, CRABP2, PCDH7, and PPIG. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of PCDH7, PPIG, RAB31, C3, and EGR.
[0022] In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of CNFN, CTSC, GBAP1, and CRABP2. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PPIG, RAB31, C3, and EGR. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PCDH7, PPIG, RAB31, and C3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of GBAP1, CRABP2, PCDH7, and PPIG.
[0023] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of SERPINB3, SERPINB4, S100A7A, PI3, KRT6A, LCN2, DEFB4A, DEFB4B, SPRR1A, IL36G, MX1, IFI27, CD36, CD24, and IL4R. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of KRT6A, SPRR1A, CD36, IL4R, LCN2, and IFI27. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CD36, IL4R, S100A7A, SERPINB4, MX1, and SERPINB3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of LCN2, IFI27, DEFB4A, IL36G, CD24, and PI3.
[0024] In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of IL4R, LCN2, and IFI27. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PI3, IFI27, and SERPINB3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of IL4R, S100A7A, and MX1. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of CD36, LCN2, and SERPINB4.
[0025] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of MTCO1P12, MTATP6P1, CLSTN1, PDPN, LDLRAD2, and GSTM3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of AL158847.1, DAD1, LDLRAD2, ZNF395, MGMT, and AL136982.4. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of NREP, PPIF, PRIM1, AL136982.5, MTATP6P1, and SMPD3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of PDPN, TXNRD1, GSTM3, GPSM1, GLRX, and USP2.
[0026] In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of MTCO1P12, CLSTN1, and GSTM3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of NREP, PPIF, and PRIM1. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of AL136982.5, MTATP6P1, and SMPD3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PDPN, TXNRD1, and GSTM3.
[0027] Further provided herein are microneedle devices, methods, and systems for characterizing an autoimmune disease in a subject, and the likelihood that the subject may respond positively to a given therapeutic agent for treating said subject's autoimmune disease.
[0028] Aspects of the present disclosure include a microneedle device comprising: (i) a plurality of microneedles protruding from a front surface of a microneedle base substrate; (ii) a rear surface of the microneedle base substrate; and (iii) a microneedle region including a minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate; and a support substrate adjacent to at least one side of the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate and including a depth of the support substrate, the depth of the support substrate being greater than the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate.
[0029] Another aspect of the present disclosure includes a microneedle device comprising: a microneedle region including a plurality of microneedles protruding from a front surface of a microneedle base substrate, the microneedle base substrate further comprising a rear surface, the rear surface including a recess immediately behind at least a portion of the microneedle region; and a support substrate adjacent to at least one side of the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate. In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate is between about 1 μm and about 500 μm less than the depth of the support substrate. In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate is between about 150 μm and about 350 μm. In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate and the depth of the support substrate comprises a ratio of about 1:5, hi some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate and the depth of the support substrate comprises a ratio of at least about 0.1:5, at least about 0.5:5, at least about 1:5, at least about 2:5, at least 3:5, at least 4:5, at least 1:1, at least 1:2, at least 1:3, at least 1:4, at least about 1:10, at least about 1:15, at least about 1:20, at least about 1:25, or at least about 1:50.In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate and the depth of the support substrate comprises a ratio of at most about 0.1:5, at most about 0.5:5, at most about 1:5, at most about 2:5, at most 3:5, at most 4:5, at most 1:1, at most 1:2, at most 1:3, at most about 1:4, at most 1:10, at most 1:15, at most about 1:20, at most about 1:25, or at most about 1:50. In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate and the depth of the support substrate comprises a ratio of at least about 2:1, at least about 3:1, at least about 3:2, at least about 4:1, at least 5:1, at least 5:3, at least 6:1, at least 7:1, at least 10:1, at least 15:1, at least about 20:1, at least about 25:1, or at least about 50:1. In some embodiments, the minimum distance between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate and the depth of the support substrate comprises at most about a 2:1 ratio, at most about a 3:1 ratio, at most about a 3:2 ratio, at most about a 4:1 ratio, at most about a 5:1 ratio, at most about a 5:3 ratio, at most about a 6:1 ratio, at most about a 7:1 ratio, at most about a 10:1 ratio, at most about a 15:1 ratio, at most about a 20:1 ratio, at most about a 25:1 ratio, or at most about a 50:1 ratio. In some embodiments, the microneedle region comprises a perimeter, and the support substrate is adjacent to at least half of the perimeter. In some embodiments, the rear surface of the microneedle base substrate is not coplanar with the rear surface of the support substrate. In some embodiments, the front surface of the microneedle base substrate is not coplanar with the surface of the support substrate. In some embodiments, the plurality of microneedles are plasma treated. In some embodiments, a plurality of probes are coupled to the microneedles of said plurality of microneedles. In some embodiments, said plurality of probes comprises a negative charge.In some embodiments, the plurality of microneedles comprises a polyolefin resin. In some embodiments, the polyolefin resin comprises one or both of Zeonor 1020R and Zeonor 690R. In some embodiments, the microneedles of the plurality of microneedles are non-dissolvable. In some embodiments, the microneedles of the plurality of microneedles are pyramidal. In some embodiments, the microneedles of the plurality of microneedles are solid. In some embodiments, the angle between the base of the microneedle and the microneedle base substrate is between about 60° and about 90°. In some embodiments, the recess directly behind the at least portion of the microneedle region comprises a width greater than a width of a mechanical applicator.
[0030] Another aspect of the present disclosure includes a kit, the kit including (a) the device of some aspects described herein, and (b) a mechanical applicator that fits within the recess directly behind at least a portion of the microneedle region. In some embodiments, at least one of the plurality of microneedles is coupled to a nucleic acid probe. In some embodiments, the nucleic acid probe comprises a homopolymer sequence. In some embodiments, the homopolymer sequence comprises thymine or uracil. In some embodiments, the nucleic acid probe is covalently attached to the microneedle. In some embodiments, the support substrate includes a fiducial marker. In some embodiments, no more than three microneedles of the plurality of microneedles are less than 600 μm in length or greater than 1050 μm in length.
[0031] Another aspect of the present disclosure includes a method of preparing a biological sample from a subject, the method comprising the steps of contacting the skin of the subject with a microneedle device, the microneedle device comprising a plurality of nucleic acid probes attached to microneedles; applying pressure to the microneedle device such that the microneedle device penetrates the skin of the subject; penetrating the microneedle device into the skin of the subject for 10 minutes or less to obtain a ribonucleic acid (RNA) sample hybridized to the nucleic acid probes, the RNA sample comprising a population of RNA fragments comprising about 700 bases or more and a population of RNA fragments comprising about 150 bases to about 200 bases, and the ratio of the population of RNA fragments comprising about 700 bases or more to the population of RNA fragments comprising about 150 bases to about 200 bases is greater than 1; and removing the microneedle device from the skin of the subject, wherein after removal from the skin of the subject, the microneedle device comprises the RNA sample hybridized to the nucleic acid probes. In some embodiments, the RNA sample is substantially free of contaminants. In some embodiments, the method includes allowing the microneedle device to penetrate the skin of the subject for about 5 minutes.
[0032] Another aspect of the present disclosure includes a method for predicting an individual patient's response to certain biologic drugs according to the mechanism of action of such drugs in order to optimize treatment selection. By using a machine learning approach, for example, by using a machine learning derived classifier to predict response to anti-IL-17 and anti-IL-23 biologics in patients with psoriasis with a high level of positive predictive value, a classifier is trained to predict the patient's response to either the IL-17, IL-23 class, or TNF class of biologics with a high level of positive predictive value using baseline transcriptomic biomarkers (e.g., specific genes).
[0033] Another aspect of the present disclosure includes an algorithm for predicting response to biologic agents (e.g., anti-IL-17, anti-IL-23) used to treat psoriasis patients by comparing the baseline transcriptome with the clinical response to the biologic drug after initial treatment, e.g., 12 weeks later.
[0034] Another aspect of the present disclosure provides a method for determining whether a subject's skin lesions are responsive to an autoimmune disease therapeutic agent, the method comprising: penetrating the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to the microneedles; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; quantifying the RNA molecules comprising sequence reads associated with a positive response to the autoimmune disease therapeutic agent to determine an expression level of at least one gene; and applying a trained algorithm to the expression levels, wherein the trained algorithm has a positive predictive value of greater than 80% for predicting response to the autoimmune disease therapeutic agent.
[0035] Another aspect of the present disclosure provides a method for determining whether a subject's skin lesion is responsive to an autoimmune disease therapeutic agent, the method comprising: penetrating the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to solid microneedles; removing the microneedle device from the subject's skin, thereby obtaining RNA molecules from the subject; performing high-throughput sequencing on the RNA molecules to generate sequence reads; quantifying the RNA molecules comprising sequence reads associated with a positive response to the autoimmune disease therapeutic agent to determine the expression level of at least one gene; and applying a trained algorithm to the expression level of the at least one RNA molecule, wherein the trained algorithm predicts whether the subject with the skin lesion will be responsive to an IL-17-mediated treatment, an IL-23-mediated treatment, a TNFα-mediated treatment, or any combination thereof. In some embodiments, the subject is responsive to an IL-17-mediated treatment, an IL-23-mediated treatment, and a TNFα-mediated treatment. In some embodiments, the at least one gene comprises at least two genes, three genes, four genes, or five genes. In some embodiments, the at least one gene includes at least two, three, four, five, six, seven, eight, nine, or ten genes in Table 6, Table 12, or Table 13. In some examples, the at least one gene includes at least two genes that do not share a common upregulator. In some embodiments, the autoimmune disorder is psoriasis. In some cases, the subject has a PASI of more than 8. In some cases, the subject has a PASI of at least 75 after treating the subject with an autoimmune therapeutic agent. In some cases, the RNA includes mRNA or microRNA and is converted into cDNA, which is then sequenced using next-generation sequencing. In some embodiments, the recommended therapeutic agent includes one or more autoimmune therapeutic agents for an autoimmune disease or condition.In some embodiments, the recommended treatment includes etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab, or any combination thereof.
[0036] In some embodiments, the methods described herein further comprise performing high-throughput sequencing on the RNA biomarkers to generate one or more sequence reads for the subject; quantifying RNA molecules comprising the one or more sequence reads for the subject using a known signature of the sequence reads, where the known signature of the sequence reads is associated with a positive response to a recommended treatment, thereby obtaining aligned sequence reads; and classifying the subject as having a likelihood of a positive response to the recommended therapeutic agent by applying a trained algorithm to the aligned sequence reads, where the trained algorithm comprises a positive predictive value of greater than 50% for predicting a positive response to the recommended therapeutic agent. In some embodiments, the trained algorithm has a negative predictive value of greater than 50%. INCORPORATION BY REFERENCE
[0037] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief explanation of the drawings]
[0038] The novel features of the invention are set forth with particularity in the appended claims. For a better understanding of the features and advantages of the present invention, reference should be made to the following detailed description that sets forth illustrative embodiments in which the principles of the invention are utilized and the accompanying drawings. [Figure 1] 1 shows a cross section of a microneedle device described herein. [Figure 2] This shows a detailed cross section of FIG. [Figure 3]FIG. 1 shows a front view of a microneedle device described herein. [Figure 4] 1 shows a microneedle of a microneedle device described herein. [Figure 5A] Figure 5 shows the quality of various RNA samples collected using the microneedle device described herein, as measured by the length of the RNA fragments contained in the sample. Figure 5A shows an undegraded sample. [Figure 5B] 5A and 5B show the quality of various RNA samples collected using the microneedle device described herein, as measured by the length of the RNA fragments contained in the samples. Figures 5B and 5C show degraded samples. [Figure 5C] 5A and 5B show the quality of various RNA samples collected using the microneedle device described herein, as measured by the length of the RNA fragments contained in the samples. Figures 5B and 5C show degraded samples. [Figure 6A] 1 shows an exemplary flow diagram of a method for treating one or more subjects with mild or severe skin conditions, as described in some embodiments herein. [Figure 6B] 1 shows an exemplary flow diagram of a method for preparing a biological sample and identifying one or more therapeutic agents for one or more subjects, as described in some embodiments herein. [Figure 6C] 1 shows an exemplary flow diagram for identifying activation of one or more pathways that may be associated with a disease or disorder of interest. [Figure 7] 1 shows the study patient sample enrollment and analysis flow chart. [Figure 8A] Correlation between predicted response and patient week 12 PASI change in psoriasis patients from an independent validation dataset. Figure 8A: 43 patients were treated with IL-23i. X-axis: predicted responder or non-responder; Y-axis: PASI change at week 12. Red dot: median PASI change value. [Figure 8B]Correlation between predicted response and patient week 12 PASI change in psoriasis patients from an independent validation dataset. Figure 8B: 31 patients were treated with IL-17i. X-axis: predicted responder or non-responder; Y-axis: PASI change at week 12. Red dot: median PASI change value. [Figure 8C] Correlation between predicted response and patient week 12 PASI change in psoriasis patients from an independent validation dataset. Figure 8C: 11 patients were treated with TNFαi. X-axis: predicted responder or non-responder; Y-axis: PASI change at week 12. Red dot: median PASI change value. [Figure 9] Predicted response rates among patients enrolled in the study are shown. [Figure 10] An overview of RNA-Seq analysis is shown. [Figure 11] Lesioned versus non-lesioned samples compared using punch biopsies versus Mindera patches from 66 patients in the Mindera database. [Figure 12] A heatmap generated from expression data of 17 genes identified as correlating with response to anti-IL-17 biological treatment is shown. DETAILED DESCRIPTION OF THE INVENTION
[0039] Overview Described herein are microneedle devices that include features for precise, patient-friendly sample collection, including microneedle devices that can minimize pain during the sample collection process. The devices described herein can be specifically designed to be fabricated by a scalable process. Features such as varying thickness in different regions of the devices described herein can result in uniform and precise microneedle devices. Specific features of the microneedle devices described herein can also result in sharper microneedles not described in the current state of the art. These sharper microneedles can provide an improved user or patient (e.g., subject) experience, and users may experience much less pain compared to current state-of-the-art microneedle devices. Combining the precision of the microneedle device with an improved user experience can result in more precise and accurate analysis of biological samples (e.g., a user's skin).
[0040] Generally, the microneedle device provided herein may contain a probe attached to the microneedle.In some cases, these probes are configured to bind to one or more biomarkers in a sample or tissue (for example, skin) of a subject in such a manner that allows the biomarker to be extracted for further analysis.The extracted biomarkers can be analyzed alone or in combination (for example, to generate a gene signature or gene expression profile) to provide a diagnosis or prediction of the response of a subject to drugs or other therapeutic treatments.
[0041] Furthermore, the present disclosure provides a method and system for determining gene expression profile from subject.In some cases, gene expression profile is useful for determining the appropriate treatment regimen for autoimmune disease.Therefore, the method of the present disclosure is useful for personalized medicine, and treatment is adjusted to subject based on the specific characteristics of the subject's disease.
[0042] In some embodiments, the present disclosure provides a microneedle device. In some embodiments, the microneedle device includes a microneedle region and a support substrate. The microneedle region may include a plurality of microneedles (110) protruding from a front or first surface of a microneedle base substrate, a rear surface (or second base substrate surface) (160) of the microneedle base substrate, and a minimum distance (170) between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate. In some embodiments, the minimum distance (170) between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate configures the device such that, during some methods of fabricating the device, a melting medium (e.g., a polyolefin resin described herein) fills the microneedle mold before filling the mold for the remainder of the device. In some embodiments, the minimum distance (170) between the front surface of the microneedle base substrate and the rear surface of the microneedle base substrate configures the device to include uniform and / or sharp microneedles. In some embodiments, uniform and / or sharp microneedles provide an improved user experience for subjects using the device. In some embodiments, the improved user experience comprises a reduction in pain experienced by the subject using the device.
[0043] The present disclosure provides a microneedle device for in situ detection and acquisition of biomarkers from a subject. The microneedle-based device may contain one or more microneedles that can penetrate biological barriers such as the skin or mucous membrane. In many cases, the microneedles are non-invasive or minimally invasive. When multiple microneedles are present, the device may further include a planar substrate that supports the microneedles. The substrate can be made of the same material as the microneedles. Furthermore, it can be made of a different material.
[0044] Microneedle Device Microneedle devices of the present disclosure may include a base substrate including a microneedle region and a support substrate. Figure 1 shows a side view of an exemplary microneedle device (100) including microneedles (110) on a microneedle base substrate (120). The microneedle base substrate includes a front surface (140) (used interchangeably herein with the term "first base substrate surface") from which the microneedles (110) protrude (or the first base substrate surface), and a rear surface (160) (used interchangeably herein with the term "second base substrate surface"). The device may include a support substrate (130) adjacent to at least one side of the inner microneedle base substrate (120), the support substrate being connected to or integral with the microneedle base substrate. In some embodiments, an angle is formed between the rear surface of the microneedle base substrate (160) and the adjacent support substrate (130).
[0045] In some embodiments, the angle formed between the rear surface of the microneedle base substrate (160) and the adjacent support substrate (130) is a right angle or an obtuse angle, e.g., about 90° to about 179°. The angle (Θ) formed between the rear surface of the microneedle base substrate (160) and the adjacent support substrate (130) generally refers to the angle across a region of space within the device, and adjacent support substrates generally include a complementary angle (α) across the substrate, which is often an acute angle (e.g., between 1° and 90°). In some embodiments, the angle (Θ) formed between the rear surface of the microneedle base substrate and the adjacent support substrate is about 110°. In some embodiments, the angle (Θ) formed between the rear surface of the microneedle base substrate and the adjacent support substrate is from about 90° to about 100°, from about 90° to about 110°, from about 90° to about 120°, from about 90° to about 130°, from about 90° to about 140°, from about 90° to about 150°, from about 90° to about 160°, from about 90° to about 170°, from about 90° to about 179°, approximately 100° to approximately 110°, approximately 100° to approximately 120°, approximately 100° to approximately 130°, approximately 100° to approximately 140°, approximately 100° to approximately 150°, approximately 100° to approximately 160°, approximately 100° to approximately 170°, approximately 100° to approximately 179°, approximately 110° to approximately 120°, approximately 110° to approximately 130°, approximately 110° to approximately 140°, approximately 110° to approximately 150° , about 110° to about 160°, about 110° to about 170°, about 110° to about 179°, about 120° to about 130°, about 120° to about 140°, about 120° to about 150°, about 120° to about 160°, about 120° to about 170°, about 120° to about 179°, about 130° to about 140°, about 130° to about 150°, about 130° to about 160°, about 1 The angle is typically between 30° and about 170°, between 130° and about 179°, between 140° and about 150°, between 140° and about 160°, between 140° and about 170°, between 140° and about 179°, between 150° and about 160°, between 150° and about 170°, between 150° and about 179°, between 160° and about 170°, between 160° and about 179°, or between 170° and about 179°. In some embodiments, the angle formed between the rear surface of the microneedle base substrate and the adjacent support substrate is about 90°, about 100°, about 110°, about 120°, about 130°, about 140°, about 150°, about 160°, about 170°, or about 179°.In some embodiments, the angle formed between the rear surface of the microneedle-based substrate and the adjacent support substrate is at least about 90°, about 100°, about 110°, about 120°, about 130°, about 140°, about 150°, about 160°, or about 170°. In some embodiments, the angle formed between the rear surface of the microneedle-based substrate and the adjacent support substrate is at most about 100°, about 110°, about 120°, about 130°, about 140°, about 150°, about 160°, about 170°, or about 179°.
[0046] The resulting shape of the support substrate (130) can further affect the rate and uniformity of polymer and / or resin flow into a mold part resembling the structure of the device during device fabrication. In some embodiments, the resulting shape of the support substrate (130) is circular. In some embodiments, the resulting shape of the support substrate (130) is linear.
[0047] In some cases, the microneedle arrangement is in a circular pattern with a microneedle portion having a radius of about 0.95 mm to about 4.15 mm. In some embodiments, the radius is about 4.0 mm. In some embodiments, the radius is about 0.95 mm to about 1.4 mm, about 0.95 mm to about 1.75 mm, about 0.95 mm to about 2.15 mm, about 0.95 mm to about 2.55 mm, about 0.95 mm to about 2.95 mm, about 0.95 mm to about 3.35 mm, about 0.95 mm to about 3.75 mm, about 0.95 mm to about 4.15 mm, about 1.4 mm ~ approx. 1.75 mm, approx. 1.4 mm ~ approx. 2.15 mm, approx. 1.4 mm ~ approx. 2.55 mm, approx. 1.4 mm ~ approx. 2.95 mm, approx. 1.4 mm ~ approx. 3.35 mm, approx. 1. 4mm~approx.3.75mm, approx.1.4mm~approx.4.15mm, approx.1.75mm~approx.2.15mm, approx.1.75mm~approx.2.55mm, approx.1.75mm~approx.2.95mm , about 1.75mm~about 3.35mm, about 1.75mm~about 3.75mm, about 1.75mm~about 4.15mm, about 2.15mm~about 2.55mm, about 2.15mm~ Approximately 2.95mm, approximately 2.15mm to approximately 3.35mm, approximately 2.15mm to approximately 3.75mm, approximately 2.15mm to approximately 4.15mm, approximately 2.55mm to approximately 2.95mm, approximately 2 In some embodiments, the radius is about 0.95 mm, about 1.4 mm, about 1.75 mm, about 2.15 mm, about 2.55 mm, about 2.95 mm, about 3.35 mm, about 3.75 mm, about 3.35 mm, about 4.15 mm, or about 3.75 mm. In some embodiments, the radius is at least about 0.95 mm, about 1.4 mm, about 1.75 mm, about 2.15 mm, about 2.55 mm, about 2.95 mm, about 3.35 mm, or about 3.75 mm, hi some embodiments, the radius is at most about 1.4 mm, about 1.75 mm, about 2.15 mm, about 2.55 mm, about 2.95 mm, about 3.35 mm, about 3.75 mm, or about 4.15 mm.
[0048] In some cases, the microneedle arrangement is a rectilinear square pattern having an overall edge length of about 2.14 mm to about 9.34 mm. In some embodiments, the distance is about 4.0 mm. In some embodiments, the distance is about 2.14 mm to about 3.04 mm, about 2.14 mm to about 3.94 mm, about 2.14 mm to about 4.84 mm, about 2.14 mm to about 5.74 mm, about 2.14 mm to about 6.64 mm, about 2.14 mm to about 7.54 mm, about 2.14 mm to about 8.44 mm, about 2.14 mm to about 9.34 mm, about 3.04 mm. mm ~ approx. 3.94 mm, approx. 3.04 mm ~ approx. 4.84 mm, approx. 3.04 mm ~ approx. 5.74 mm, approx. 3.04 mm ~ approx. 6.64 mm, approx. 3.04 mm ~ approx. 7.54 mm, Approximately 3.04mm to approximately 8.44mm, approximately 3.04mm to approximately 9.34mm, approximately 3.94mm to approximately 4.84mm, approximately 3.94mm to approximately 5.74mm, approximately 3.94mm to approximately 6. 64mm, about 3.94mm to about 7.54mm, about 3.94mm to about 8.44mm, about 3.94mm to about 9.34mm, about 4.84mm to about 5.74mm, about 4.84 mm ~ approx. 6.64 mm, approx. 4.84 mm ~ approx. 7.54 mm, approx. 4.84 mm ~ approx. 8.44 mm, approx. 4.84 mm ~ approx. 9.34 mm, approx. 5.74 mm ~ approx. 6.64 mm, The distance is about 5.74 mm to about 7.54 mm, about 5.74 mm to about 8.44 mm, about 5.74 mm to about 9.34 mm, about 6.64 mm to about 7.54 mm, about 6.64 mm to about 8.44 mm, about 6.64 mm to about 9.34 mm, about 7.54 mm to about 8.44 mm, about 7.54 mm to about 9.34 mm, or about 8.44 mm to about 9.34 mm. In some embodiments, the distance is about 2.14 mm, about 3.04 mm, about 3.94 mm, about 4.84 mm, about 5.74 mm, about 6.64 mm, about 7.54 mm, about 8.44 mm, or about 9.34 mm. In some embodiments, the distance is at least about 2.14 mm, about 3.04 mm, about 3.94 mm, about 4.84 mm, about 5.74 mm, about 6.64 mm, about 7.54 mm, or about 8.44 mm. In some embodiments, the distance is at most about 3.04 mm, about 3.94 mm, about 4.84 mm, about 5.74 mm, about 6.64 mm, about 7.54 mm, about 8.44 mm, or about 9.34 mm.
[0049] In some embodiments, the surface from which the microneedles protrude and which is applied to the tissue of interest may be referred to as the bottom or front surface, and in some embodiments, the surface (160) opposite the surface from which the microneedles protrude may be referred to as the back or top surface.
[0050] In some embodiments, the microneedle base substrate (120) is defined by the presence of microneedles. The microneedle base substrate (120) may be thinner and / or narrower than the support substrate (130), for example, between the front surface of the microneedle base substrate (140) and the D BS The distance between the rear surface of the microneedle base substrate (160), referred to as (170) in FIG. 1, is D SS The depth difference between the microneedle base substrate (120) and the support substrate (130) is smaller than the distance between each adjacent surface of the support substrate (130) referred to as the depth difference ((180) in FIG. 1). The depth difference between the microneedle base substrate (120) and the support substrate (130) can form a recess in the device, with the recess located adjacent to the microneedle base substrate (120). This structural feature is particularly advantageous because having a narrow microneedle base substrate (120) improves the flow and / or penetration of the polymer / resin used to fabricate the device into a mold resembling the structure of the device during manufacturing. Specifically, the flow and / or penetration of the polymer / resin into the portion of the mold corresponding to the microneedle is increased due to this structural feature of the depth difference between the microneedle base substrate (120) and the support substrate (130), resulting in more uniform and sharp microneedles. Sharper microneedles may cause less tissue damage when inserted and therefore cause less pain to the subject. More uniform microneedles result in more standard and scalable manufacturing methods.
[0051] In some embodiments, a narrower microneedle base substrate can also concentrate pressure through the microneedles when the device is applied to skin or other tissue. In some cases, the minimum distance between the front surface of the microneedle base substrate (140) and the rear surface of the microneedle base substrate (150) is about 1 μm to about 500 μm less than the distance from the front surface of the support substrate to the rear surface of the support substrate.
[0052] In some embodiments, the microneedle base substrate (D BS ) and the supporting substrate (D SS In some embodiments, the difference in depth between the microneedle base substrate (D BS ) and the supporting substrate (D SS ) is about 250 μm. BS ) and the supporting substrate (D SS) is about 1 μm to about 50 μm, about 1 μm to about 100 μm, about 1 μm to about 150 μm, about 1 μm to about 200 μm, about 1 μm to about 250 μm, about 1 μm to about 300 μm, about 1 μm to about 350 μm, about 1 μm to about 400 μm, about 1 μm to about 450 μm, about 1 μm to about 500 μm, about 1 μm to about 550 μm, about 50 μm to about 100 μm, about 50 μm to about 150 μm, about 50 μm to about 200 μm, about 50 μm to about 250 μm, about 50 μm to about 300 μm, about 50 μm to about 350 μm, about 50 μm to about 400μm, approx. 50μm~approx. 450μm, approx. 50μm~approx. 500μm, approx. 50μm~approx. 550μm, approx. m, about 100 μm to about 400 μm, about 100 μm to about 450 μm, about 100 μm to about 500 μm, about 100 μm to about 550 μm, about 150 μm to about 200 μm, about 150 μm to about 250 μm, about 150 μm to about 300 μm, about 150 μm to about 350 μm, Approx. 150 μm to approx. 400 μm, approx. 150 μm to approx. 450 μm, approx. 150 μm to approx. 500 μm, approx. 150 μm to approx. 550 μm, approx. 200 μm to approx. 200μm to about 450μm, about 200μm to about 500μm, about 200μm to about 550μm, about 250μm to about 300μm, about 250μm to about 350μm, about 250μm to about 400μm, about 250μm to about 450μm, about 250μm to about 500μm, about 25 0 μm to about 550 μm, about 300 μm to about 350 μm, about 300 μm to about 400 μm, about 300 μm to about 450 μm, about 300 μm to about 500 μm, about 300 μm to about 550 μm, about 350 μm to about 400 μm, about 350 μm to about 450 μm, about 350 μm to about 500 μm, about 350 μm to about 550 μm, about 400 μm to about 450 μm, about 400 μm to about 500 μm, about 400 μm to about 550 μm, about 450 μm to about 500 μm, about 450 μm to about 550 μm, or about 500 μm to about 550 μm.In some embodiments, the depth difference between the microneedle base substrate and the support substrate is about 1 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, about 500 μm, or about 550 μm. In some embodiments, the microneedle base substrate (D BS ) and the supporting substrate (D SS ) is at least about 1 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, or about 500 μm. In some embodiments, the depth difference between the microneedle base substrate and the support substrate is at most about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, about 500 μm, or about 550 μm.
[0053] In some cases, the front surface of the microneedle base substrate and the microneedle base substrate (D BS The minimum distance between the front and rear surfaces of the interior and the peripheral portions is about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.
[0054] In some cases, the microneedle portion or region includes a periphery and a peripheral region or support substrate, and is adjacent to at least half of the periphery. In some cases, the rear surface of the microneedle base substrate is not coplanar with the rear surface of the support substrate. In some cases, the front surface of the microneedle base substrate is not coplanar with the surface of the support substrate.
[0055] FIG. 2 provides a detailed view of the circled area in FIG. 1. In some embodiments, the interior may also have ridges (200) surrounding the microneedle region. The ridges may protrude from the surface from which the microneedles protrude. In some embodiments, the ridge height, HR (210 in FIG. 2) may be about 250 μm. In some embodiments, the ridge height, HR, may be about 50 μm, 100 μm, 150 μm, 200 μm, 250 μm, 254 μm, 300 μm, 350 μm, 400 μm, or 450 μm. In some cases, the ridges surrounding the interior may increase or maintain the surface tension of tissue, such as skin, when the device is applied to the tissue. In some cases, the angle formed between the ridges and the bottom surface is about 50 degrees to about 85 degrees. In some cases, the angle formed between the ridges and the bottom surface is about 45 degrees. In some cases, the angle formed between the ridge and the bottom surface is between about 5° and about 10°, between about 5° and about 20°, between about 5° and about 30°, between about 5° and about 40°, between about 5° and about 50°, between about 5° and about 60°, between about 5° and about 70°, between about 5° and about 80°, between about 5° and about 85°, between about 10° and about 20°, between about 10° and about 30°, between about 10° and about 40°, between about 10° and about 50°, between about 10° and about 60°, between about 10° and about 70°, between about 10° and about 80°, between about 10° and about 85°, between about 20° and about 30°, between about 20° and about 40°, between about 20° and about 50°, between about 20° and about 60°, between about 20° and about 70°, , about 20° to about 80°, about 20° to about 85°, about 30° to about 40°, about 30° to about 50°, about 30° to about 60°, about 30° to about 70°, about 30° to about 80°, about 30° to about 85°, about 40° to about 50°, about 40° to about 60°, about 40° to about 70°, about 40° to about 80°, about 40° to about 85°, about 50° to about 60°, about 50° to about 70°, about 50° to about 80°, about 50° to about 85°, about 60° to about 70°, about 60° to about 80°, about 60° to about 85°, about 70° to about 80°, about 70° to about 85°, or about 80° to about 85°. In some cases, the angle formed between the ridge and the bottom surface is about 5°, about 10°, about 20°, about 30°, about 40°, about 50°, about 60°, about 70°, about 80°, or about 85°.In some cases, the angle formed between the ridge and the base is at least about 5°, about 10°, about 20°, about 30°, about 40°, about 50°, about 60°, about 70°, or about 80°. In some cases, the angle formed between the ridge and the base is at most about 10°, about 20°, about 30°, about 40°, about 50°, about 60°, about 70°, about 80°, or about 85°.
[0056] In some embodiments, the microneedle portion may also have a lower bottom surface than the bottom surface of the support substrate, e.g., the bottom surface of the microneedle portion may protrude further from the device than the bottom surface of the support substrate. In some cases, the bottom surface may overlap the base of the microneedle. In some cases, the inner bottom surface may protrude approximately 250 μm. In some cases, the inner bottom surface may protrude approximately 0 μm, 50 μm, 100 μm, 150 μm, 200 μm, 250 μm, 300 μm, 350 μm, 400 μm, or 450 μm. In some cases, the inner protruding bottom surface may increase or maintain the surface tension of tissue, such as skin, when the device is applied to the tissue.
[0057] In some embodiments, the support substrate (130) may be formed of the same material as the microneedle portion and the microneedles. The support substrate may be thicker than the interior. In some cases, the periphery includes fiducial markers. Figure 3 provides a front view of the microneedle device (100) with fiducial markers (310).
[0058] In some embodiments, the device of the present disclosure may be manufactured using a mold. In some cases, the device may be manufactured by transferring a resin (e.g., a polyolefin resin) into a device mold. The mold may include a plurality of cavities for forming a plurality of microneedles, the cavities being for forming an interior portion containing the plurality of microneedles, and one or more cavities for forming one or more peripheral portions adjacent to the interior portion, the width of the interior portion being smaller than the width of the peripheral portion. In some cases, the polyolefin resin may generate a plurality of microneedles before generating the interior portion. In some cases, the molding resin may be plasma-treated to modify the surface.
[0059] In some embodiments, devices of the present disclosure may be manufactured using injection molding. In some cases, devices may be manufactured by injecting heated (e.g., molten) material (e.g., a polyolefin resin described herein) into a mold for the device. The mold may include multiple cavities for forming multiple microneedles, a cavity for forming an interior containing the multiple microneedles, and one or more cavities for forming one or more peripheral portions adjacent to the interior, where the width (e.g., depth and / or thickness) of the interior is smaller than the width of the peripheral portions. In some cases, the heated material may generate the multiple microneedles before generating the interior or microneedle portion.
[0060] In some cases, the entire device may be plasma treated, while in other cases, only a portion of the device, such as a microneedle, is plasma treated. In some cases, a method for plasma treating a device or a portion thereof includes the steps of preparing the device or a portion thereof, placing the device or a portion thereof in a plasma vacuum chamber, closing the plasma vacuum chamber to create a sufficient vacuum seal, evacuating any gas present in the chamber, pumping plasma treatment gas into the plasma vacuum chamber to a desired pressure, allowing gas plasma to be generated at a desired power for a desired time, evacuating the chamber of the plasma-treated gas, and removing the device or a portion thereof.
[0061] In some cases, the entire device may be excimer laser treated, while in other cases, only a portion of the device, such as a microneedle, is excimer laser treated. In some cases, a method for excimer laser treating a device or portion thereof includes the steps of preparing the device or portion thereof, placing the device or portion thereof in an excimer laser treatment chamber, closing the excimer laser treatment chamber, evacuating any gas present in the chamber, introducing a suitable excimer laser treatment gas into the excimer laser treatment chamber to provide sufficient absorption of the radiative laser energy by the device or portion thereof, allowing the excimer laser to radiate for a desired time and at a desired power, evacuating the excimer laser treatment gas, and removing the device or portion thereof.
[0062] In some cases, one or more probes of the plurality of probes are attached to one or more microneedles of the plurality of microneedles. The probes can be covalently or non-covalently attached. In some cases, the probes are attached via a linker or spacer. In some cases, the probes are attached to the microneedles to achieve maximum packing density on the surface of the microneedles.
[0063] probe In some embodiments, the microneedles contain probes capable of binding to tissue and extracting biomarkers from the tissue. Multiple probes can be attached to the microneedles of the present disclosure. In some cases, the probes contain polynucleotides (e.g., DNA, RNA, cDNA, cRNA, etc.). Often, polynucleotide probes are designed to bind to or hybridize with specific polynucleotide biomarkers. The present disclosure also provides methods and devices for detecting peptide or protein biomarkers. In these embodiments, the probes attached to the microneedles can specifically recognize and bind to target peptides or proteins of interest. The probes can be any substance capable of binding to a specific peptide or protein biomarker. They can be, for example, proteins (e.g., antibodies, antigens or fragments thereof), carbohydrates, or polynucleotides. The polynucleotides can have sequence specificity for the biomarker, for example, by having a complementary sequence.
[0064] In some embodiments, the probes used often depend on the one or more biomarkers to be detected. Thus, depending on the nature and number of biomarkers to be detected, the number of probes immobilized on the microneedle can be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. In some cases, the total number of probes immobilized on the microneedle can be from about 1 to about 1,000, from about 1 to about 10,000, from about 1 to about 100,000,000, from about 1 to about 100,000,000, from about 1,000 to about 100,000,000, from about 10,000 to about 100,000,000, or from about 10,000,000 to about 100,000,000. In some cases, the total number of probes in the microneedle is at least about 10, about 20, about 50, about 100, about 500, about 1000, about 10,000, about 100,000, about 1,000,000, about 10,000,000, or about 100,000,000 probes. In some cases, the total number of probes in the microneedle is less than about 10, about 100, about 1000, about 10,000, about 100,000, about 1,000,000, about 10,000,000, or about 100,000,000 probes.
[0065] In some embodiments, biomarker probes can be immobilized on multiple microneedles in the devices of the present disclosure, as further described herein, particularly for detecting low concentrations of biomarkers. In some cases, a single microneedle contains multiple different probes capable of binding or detecting the same biomarker. In some cases, a single microneedle contains at least 2 different probes, at least 3 different probes, at least 4 different probes, at least 6 different probes, at least 8 different probes, at least 10 different probes, at least 15 different probes, at least 20 different probes, or at least 50 different probes. In some cases, the same microneedle contains more than 50 different types of probes for the same biomarker.
[0066] In some cases, the same microneedle contains multiple different probes. The different probes can be specific to the same biomarker or different biomarkers. A microneedle can contain at least 2 different probes, at least 10 different probes, at least 100 different probes, at least 200 different probes, at least 500 different probes, at least 1,000 different probes, at least 5,000 different probes, or at least 10,000 different probes.
[0067] In some cases, the individual probes of the plurality of probes are identical (e.g., identical copies of the same polynucleotide or antibody). In some embodiments, a microneedle can be associated with multiple copies of the same probe (e.g., 2, 5, 10, 50, 100, 1,000, 5,000, 7,500, 10,000, or more than 50,000 copies of the same probe). For example, a microneedle can contain multiple copies of a polynucleotide probe designed to hybridize to the same polymorphism or biomarker. In some cases, a microneedle can contain multiple copies of an antibody probe designed to bind to the same epitope.
[0068] In some cases, the probe may bind to a type of biomarker, such as mRNA. A probe that binds to mRNA may include a polynucleotide having or including a homopolymeric sequence. In some cases, the probe includes one or more thymine residues. For example, in some cases, the probe includes at least 1, at least 5, at least 10, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, or at least 200 thymine residues (e.g., thymidine residues). In some cases, the probe binds to the poly-A tail of an mRNA molecule. In some cases, the probe includes a homopolymeric sequence. In these cases, the homopolymeric sequence is configured to bind to a complementary homopolymeric sequence. In some cases, the probe includes a sequence of thymines that binds to the poly-A tail of an mRNA. The probe may include any fragment of a sequence of consecutive thymines. In some embodiments, the sequence of consecutive thymines includes about 250 consecutive thymines. In some embodiments, the sequence of consecutive thymines comprises about 200 consecutive thymines. In some embodiments, the sequence of consecutive thymines comprises about 150 consecutive thymines. In some embodiments, the sequence of consecutive thymines comprises about 100 consecutive thymines. In some embodiments, the sequence of consecutive thymines comprises about 50 consecutive thymines. In some embodiments, the sequence of consecutive thymines comprises about 50-250 consecutive thymines. In some cases, the probe may contain thymines interspersed with other bases.
[0069] In some cases, the microneedle includes a polynucleotide probe. The probes can be designed to detect different biomarkers (e.g., nucleic acid molecules, proteins) associated with the same disease, disorder, or condition. In some cases, a first probe can recognize a disease-associated polymorphism (e.g., DNA polymorphism, RNA polymorphism), and a second probe can recognize a different polymorphism associated with the same disease. For example, a first nucleic acid probe on the microneedle can be designed to detect a first polymorphism in an RNA biomarker associated with onchocerciasis, a skin disease. A second nucleic acid probe on the microneedle can be designed to detect a second polymorphism in an RNA biomarker associated with onchocerciasis. The polymorphism can be, for example, a single nucleotide polymorphism (SNP). Genetic and genomic variations can include a single SNP or multiple SNPs. SNPs can occur at a single locus or at many loci. Individuals who carry a particular SNP on an allele at one locus can predictably carry additional SNPs at other loci. Correlations between SNPs can provide associations between alleles that predispose individuals to a disease or disease. In some cases, different polynucleotide probes are designed to detect different biomarkers associated with different diseases. For example, one probe can detect a disease biomarker (e.g., a polynucleotide), while the other probe can detect a housekeeping gene or gene product (e.g., a polypeptide). In some cases, microneedles are attached to polynucleotides, polypeptides, or a mixture of polynucleotides and polypeptides. In some cases, the probes can contain negative charges. In some cases, multiple probes can contain residual negative charges. In some cases, the microneedles of the devices described herein are loaded with probes at the maximum packing density of the microneedles. The residual negative charge generated from the maximum packed microneedles can be strong enough to prevent the loaded probes from nonspecifically binding to biomarkers of no interest.
[0070] In some cases, the microneedles can also be coupled with multiple different protein or antibody probes. For example, a first antibody probe on the microneedle can be designed to detect a first epitope of an antigen associated with, for example, skin cancer. A second antibody probe can be designed to detect a second epitope associated with the antigen. Or, in some cases, the second antibody probe can detect an epitope associated with a different skin disease and / or a different antigen.
[0071] In some cases, the present disclosure provides a microneedle device comprising a set of microneedles, each microneedle in the set comprising an identical probe or set of probes. In some embodiments, identical probes are attached to multiple microneedles of the device. Identical probes can be attached to, for example, about 1% of the microneedles, about 5% of the microneedles, about 10% of the microneedles, about 50% of the microneedles, about 90% of the microneedles, about 95% of the microneedles, or about 100% of the microneedles. In some embodiments, identical probes are attached to no more than 5% of the microneedles, no more than 10% of the microneedles, no more than 25% of the microneedles, no more than 50% of the microneedles, no more than 95% of the microneedles, or no more than 99% of the microneedles.
[0072] In some cases, the plurality of microneedles may include at least one microneedle attached to a first probe and at least one microneedle attached to a second probe different from the first probe. For example, as described herein, the first probe may be a polynucleotide or polypeptide (e.g., antibody, protein) that specifically binds to a biomarker for a disease or disorder, and the second probe may be a polynucleotide or polypeptide that specifically binds to a different biomarker associated with the same disease or disorder. In some cases, the first probe may be a polynucleotide or polypeptide (e.g., antibody, protein) that specifically binds to a biomarker for a disease or disorder, and the second probe may be a polynucleotide or polypeptide that specifically binds to a different biomarker associated with a different disease, disorder, or condition. In some cases, the different diseases, disorders, or conditions are associated with the same organ. For example, the first probe may be associated with a first disease, disorder, or condition associated with the skin, and the second probe may be associated with a second disease, disorder, or condition associated with the skin or eye. In some cases, the device may include an array of microneedles, each containing a probe for detecting a biomarker associated with a different disease, disorder, or condition associated with the same organ. The array of microneedles may include more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 75, 100, 150, 200, 500, or 1000 microneedles associated with different diseases, disorders, or conditions. In some cases, the different diseases, disorders, or conditions are associated with different organs (e.g., more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 organs).
[0073] In some cases, the microneedle device includes a plurality of arrays of microneedles, and often the plurality of arrays of microneedles is suitable for multiplex reactions. In some cases, the plurality of arrays includes two or more arrays of microneedles, and the arrays are designed to detect different biomarkers. In some cases, a first array of microneedles may be designed to detect a biomarker associated with a disease, disorder, or condition, and a second array of microneedles may be designed to detect a different biomarker associated with the same disease, disorder, or condition. In some cases, a first array of microneedles may be designed to detect a biomarker associated with a disease, disorder, or condition, and a second array of microneedles may be designed to detect a different biomarker associated with a different disease, disorder, or condition. In some cases, a first array of microneedles may be designed to detect multiple biomarkers associated with a disease, disorder, or condition, and a second array of microneedles may be designed to detect multiple biomarkers associated with a different disease, disorder, or condition. In some cases, the second array of microneedles may be designed to detect a control biomarker (e.g., a housekeeping gene), either a positive or negative control.
[0074] In some embodiments, the probes are covalently bonded to the microneedles. In some embodiments, the probes are attached to the microneedles at about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the maximum packing density. The maximum packing density may be determined by the chemical structure of the microneedle surface. In some cases, a high density of probes may reduce nonspecific binding. For example, a high density of polynucleotide probes may prevent nonspecific polynucleotide binding due to residual negative charges. In some cases, the microneedles may be treated to promote high density probe attachment. For example, the microneedles may be plasma-treated. Plasma treatment may include treatment with oxygen, nitrogen, or carbon dioxide plasma to modify the surface.
[0075] Microneedle Microneedles can have multiple shapes. For example, the microneedles can be round, conical, triangular, square, rectangular, pentagonal, hexagonal, octagonal, pyramidal, or any other suitable shape. The microneedles can be sharp microneedles, blunt microneedles, or any combination thereof. For example, a device of the present disclosure including multiple sharp microneedles can be used to penetrate the skin of a subject, thereby contacting a probe on the microneedles with, for example, a biomarker. Sharp microneedles can be used to disrupt the tissue of a biological sample, such as a layer of cells or the outer membrane of a cell. Blunt microneedles can be used to contact the surface of the subject's skin, thereby contacting the microneedles with, for example, cell surface biomarkers on the skin. In some cases, the present disclosure provides microneedle devices including microneedles with different shapes (e.g., sharp microneedles and blunt microneedles). In some cases, the microneedles may be solid rather than hollow.
[0076] In some cases, the present disclosure provides a microneedle device in which all needles have the same shape. In some cases, all microneedles on the device have the same shape and dimensions within an error of 5%, 4%, 3%, 2%, 1.5%, 1%, 0.75%, 0.5%, or 0.25%. In some cases, three or fewer microneedles among the plurality of microneedles do not meet the height tolerance. For example, if the desired height of the microneedles is 950 μm, the height tolerance may be 600 μm or more and 1050 μm or less.
[0077] In some embodiments, the microneedles can have a shape that allows non-specifically bound material to be wiped off the needles as they exit the skin, in some cases, the non-specifically bound material can be wiped off by shear forces generated as the microneedles are drawn through the skin.
[0078] In some embodiments, the needle-shaped microneedles can be blunt-pointed, but are preferably sharp-pointed. In some embodiments, the microneedles have a conical structure with a base diameter generally in the range of 10 μm to 500 μm, preferably 20 μm to 200 μm. Figure 4 shows a surface of a device of the present disclosure having multiple microneedles with a base diameter less than 10 mm wide.
[0079] In some embodiments, the microneedles of the present disclosure can include a variety of diameters or base widths. The base shape of the microneedle can be, for example, circular, rectangular, triangular, square, pentagonal, hexagonal, or other geometric shapes. The microneedles of the present disclosure can have a diameter or base width of 500 μm or less, 400 μm or less, 300 μm or less, 200 μm or less, 100 μm or less, 50 μm or less, 40 μm or less, 30 μm or less, 20 prp or less, 10 prp or less, 1000 nm or less, 900 nm or less, 800 nm or less, 700 nm or less, 600 nm or less, 500 nm or less, 400 nm or less, 300 nm or less, 200 nm or less, or 100 nm or less.
[0080] In some cases, microneedles having a conical structure may have an angle of the edge of the cone relative to the base of the cone of 70° to about 90°, 71° to 89°, 72° to 88°, 73° to 86°, 73° to 84°, 73° to 80°, 74° to 78°, 74° to 76°, or 75.5° to 76°. In some cases, microneedles having a conical structure may have an angle of about 73°, 73.25°, 73.5°, 73.75°, 74°, 74.25°, 74.5°, 74.75°, 75°, 75.25°, 75.5°, 75.75°, 76°, 76.25°, 76.5°, 76.75°, or 77°. In some cases, a microneedle having a conical structure may have an angle of the edge of the cone relative to the base that is less than 73°, 73.25°, 73.5°, 73.75°, 74°, 74.25°, 74.5°, 74.75°, 75°, 75.25°, 75.5°, 75.75°, 76°, 76.25°, 76.5°, 76.75°, or 77°.
[0081] In some embodiments, the substrate and microneedles of the array can be made of various biodegradable or non-biodegradable materials. Examples of materials for the microneedles or substrate include poly(methyl methacrylate), silicon, silicon dioxide, ceramics, metals (such as stainless steel, titanium, nickel, molybdenum, chromium, and cobalt), and synthetic or natural resin materials. Some embodiments use biodegradable polymers such as polylactic acid, polyglycolide, polylactic acid-co-polyglycolide, pullulan, capronolactone, polyurethane, or polyanhydride. In some other embodiments, non-degradable materials, such as polymer polycarbonate, synthetic or natural resin materials, such as polymethacrylic acid, ethylene vinyl acetate, polytetrafluoroethylene, polysulfone, or polyoxymethylene, are used to fabricate the microneedle array. In some embodiments, the microneedles may be non-dissolvable. In some cases, the microneedles are made of thermoplastic polymers.
[0082] In some embodiments, the substrate and microneedles of the array can be made of various thermoplastic polymers. Non-limiting examples of thermoplastic polymers include acrylic polymers such as poly(methyl methacrylate) (PMMA), nylon, polyethylene, polypropylene, polystyrene, polyvinyl chloride, or Teflon. In some cases, the device of the present disclosure is made using a thermoplastic polymer selected from the group consisting of polycarbonate, poly(methyl methacrylate), polyethylene, and polypropylene.
[0083] Non-limiting examples of non-degradable polymers include, for example, silicone, hydrogels such as cross-linked poly(vinyl alcohol) and poly(hydroxyethyl methacrylate), ethylene-vinyl acetate, acyl-substituted cellulose acetate and its alkyl derivatives, partially and fully hydrolyzed alkylene-vinyl acetate copolymers, unplasticized polyvinyl chloride, cross-linked homo- and copolymers of polyvinyl acetate, cross-linked polyesters of acrylic acid and / or methacrylic acid, polyvinyl alkyl ethers, polyvinyl fluoride, polycarbonate, polyurethane, polyamide, polysulfone, styrene-acrylonitrile copolymer, cross-linked poly(ethylene oxide), poly(alkylene), poly(vinylimidazole), poly(ester), poly(ethylene terephthalate), polyphosphazene, and chlorosulfonated polyolefins, and combinations thereof. In some embodiments, the polymer comprises ethylene vinyl acetate.
[0084] Further non-limiting examples of biodegradable polymers include polyesters such as 3-hydroxypropionate, 3-hydroxybutyrate, 3-hydroxyvalerate, 3-hydroxycaproate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 3-hydroxynonanoate, 3-hydroxydecanoate, 3-hydroxyundecanoate, 3-hydroxydodecanoate, 4-hydroxybutyrate, 5-hydroxyvalerate, polylactide, or polylactic acid, including poly(d-lactic acid), poly(l-lactic acid), poly(d,l-lactic acid), polyglycolic acid and polyglycolide, poly(lactic acid-co-glycolic acid), poly(lactide-co-glycolide), poly(e-caprolactone), and polydioxanone. Polysaccharides, including starch, glycogen, cellulose, and chitin, can also be used as biodegradable materials.
[0085] In some embodiments, the substrate and microneedles of the array can be made of polyolefin resin. Examples of polyolefin resins include thermoplastic polyolefins such as polyethylene (PE), polypropylene (PP), polymethylpentene (PMP), and polybutene-1 (PB-1). Further examples of polyolefin resins include polyolefin elastomers (POE) such as polyisobutylene (PIB), ethylene propylene rubber (EPR), and ethylene propylene diene monomer (M-class) rubber (EPDM rubber). In some cases, the polyolefin resin can be a cycloolefin polymer such as Zeonor or Zeonex. In some cases, it is Zeonoris Zeonor 1020R, Zeonar 690R, or Zeonor 1060R.
[0086] In some embodiments, the microneedles used in the present disclosure typically have a length (height) ranging from 20 μm to 1 mm, preferably from 50 μm to 500 μm. The height of the microneedles can range from about 400 μm to about 1000 μm.
[0087] The microneedle devices of the present disclosure can include any number of microneedles, hi some embodiments, the devices of the present disclosure include at least 1 microneedle, at least 100 microneedles, at least 200 microneedles, at least 300 microneedles, at least 400 microneedles, at least 500 microneedles, at least 1000 microneedles, at least 3000 microneedles, or at least 5000 microneedles.
[0088] In some embodiments, a device of the present disclosure comprises up to 10,000 microneedles, up to 5,000 microneedles, up to 2,500 microneedles, up to 2,000 microneedles, up to 1,000 microneedles, up to 500 microneedles, up to 400 microneedles, up to 300 microneedles, up to 100 microneedles, up to 90 microneedles, up to 50 microneedles, up to 40 microneedles, up to 30 microneedles, up to 20 microneedles, up to 15 microneedles, up to 10 microneedles, up to 9 microneedles, up to 8 microneedles, up to 7 microneedles, up to 6 microneedles, up to 5 microneedles, up to 4 microneedles, up to 3 microneedles, up to 2 microneedles, or 1 microneedle.
[0089] In some embodiments, devices of the present disclosure include from about 1 microneedle to about 100 microneedles, from about 1 microneedle to about 200 microneedles, from about 1 microneedle to about 1000 microneedles, from about 10 microneedles to about 200 microneedles, from about 50 microneedles to about 150 microneedles, or from about 1 microneedle to about 5000 microneedles.
[0090] In some embodiments, the device of the present disclosure comprises 100 microneedles. In some embodiments, the device of the present disclosure comprises 90-110 microneedles. In some embodiments, the device of the present disclosure comprises 80-120 microneedles. In some embodiments, the device of the present disclosure comprises 50-150 microneedles.
[0091] In some embodiments, for devices including multiple microneedles, the microneedles may be present in rows on the device. In some embodiments, the rows may be spaced apart at intervals substantially equal to the spacing of the aligned needles within the rows. In some embodiments, the rows may be spaced apart at irregular intervals.
[0092] In some embodiments, the density of microneedles within the device is at least about 10 / cm 2 , about 15 / cm 2 , about 20 / cm 2 , about 25 / cm 2 , about 30 / cm 2 , about 35 / cm 2 , about 40 / cm 2 , about 45 / cm 2 , about 50 / cm 2 , about 55 / cm 2 , about 60 / cm 2 , about 65 / cm 2 , about 70 / cm 2 , about 75 / cm 2 , about 80 / cm 2 , about 85 / cm 2 , about 90 / cm 2 , about 95 / cm 2 , about 100 / cm 2 , about 110 / cm 2 , about 120 / cm 2 , about 130 / cm 2 , about 140 / cm 2 , about 150 / cm 2 , or approximately 200 / cm 2 In some embodiments, the density of microneedles within the device may be about 10 / cm 2 , about 15 / cm 2 , about 20 / cm 2 , about 25 / cm 2 , about 30 / cm 2 , about 35 / cm 2 , about 40 / cm 2 , about 45 / cm 2 , about 50 / cm 2 , about 55 / cm 2 , about 60 / cm 2 , about 65 / cm2 , about 70 / cm 2 , about 75 / cm 2 , about 80 / cm 2 , about 85 / cm 2 , about 90 / cm 2 , about 95 / cm 2 , about 100 / cm 2 , about 110 / cm 2 , about 120 / cm 2 , about 130 / cm 2 , about 140 / cm 2 , about 150 / cm 2 , or approximately 200 / cm 2 It may be less than.
[0093] In some embodiments, the center-to-center distance between two microneedles on a device of the present disclosure can be calculated to determine the density of microneedles within the device. In some embodiments, the center-to-center distance between two microneedles can be less than 1000 μm, less than 900 μm, less than 800 μm, less than 700 μm, less than 600 μm, less than 500 μm, less than 400 μm, less than 300 μm, less than 200 μm, or less than 100 μm. In some embodiments, the center-to-center distance between two microneedles can be 100 μm or less, 200 μm or less, 300 μm or less, 400 μm or less, 500 μm or less, 600 μm or less, 700 μm or less, 800 μm or less, 900 μm or less, or 1000 μm or less.
[0094] In some embodiments, the microneedles of the present disclosure can include a variety of diameters or base widths. The base shape of the microneedle can be, for example, circular, rectangular, triangular, square, pentagonal, hexagonal, or other geometric shapes. The microneedles of the present disclosure can have a diameter or base width of 500 μm or less, 400 μm or less, 300 μm or less, 200 μm or less, 100 μm or less, 50 μm or less, 40 μm or less, 30 μm or less, 20 μm or less, 10 μm or less, 1000 nm or less, 900 nm or less, 800 nm or less, 700 nm or less, 600 nm or less, 500 nm or less, 400 nm or less, 300 nm or less, 200 nm or less, or 10 nm or less.
[0095] kit In some embodiments, the present disclosure provides a kit including a microneedle device described herein. In some cases, the kit may include a microneedle device as described herein, the microneedle device including a recess behind the microneedle region, and an applicator that fits within the recess. In some cases, the applicator is a mechanical applicator. In some cases, the microneedle device includes a microneedle region including a plurality of microneedles protruding from a front surface of a microneedle base substrate, the microneedle base substrate also including a back surface, the back surface including a recess immediately behind at least a portion of the microneedle region, and a support substrate adjacent to at least one side of the microneedle base substrate, the support substrate being connected to or integral with the microneedle base substrate.
[0096] method In some embodiments, the present disclosure provides a method for obtaining a biological sample from a tissue, such as the skin, of a subject. The subject may be of any age. For example, the subject may be an elderly person, an adult, an adolescent, a pre-adolescent, a child, a toddler, or an infant. The subject may be a mammal, a bird, a fish, a reptile, or an amphibian. Non-limiting examples of subjects include humans, primates, dogs, cats, horses, pigs, and mice. The subject may be a patient. In some embodiments, the subject is a human.
[0097] In some cases, the method includes contacting a device of the present disclosure with a tissue of a subject. In some cases, the subject may contact the device with the tissue, for example, by applying the device to the skin. In some cases, the device may be applied to the subject's tissue by another person. In some cases, the tissue may be skin, and the skin may be cleansed prior to application of the device.
[0098] In some cases, the method includes contacting a device of the present disclosure with tissue, such as skin, of a subject. In some cases, the tissue is in situ tissue. In some cases, the tissue is a biopsy. In some cases, the tissue is skin tissue. Pressure can be applied to the device, thus causing the microneedles to penetrate the tissue. In some cases, pressure, such as thumb pressure, is applied manually. In other cases, pressure may be applied by an applicator. The pressure may be about 1 N / mm 2 Less than 5N / mm 2 Less than 10N / mm 2 Less than 50N / mm 2 Less than 100N / mm 2 Less than 200N / mm 2 Less than 200N / mm 2 Less than or about 1N / mm 2 ~about 200N / mm 2 The applicator may be a manual applicator or a mechanical or electronic applicator that provides uniform pressure. In some cases, one end of the applicator has a width that is smaller than the width of the recess at the rear of the microneedle portion. The front surface of the device distal to the microneedles may be referred to as the rear surface. Pressure may be applied to the entire rear surface or may be concentrated on the interior of the device 120 at the rear surface.
[0099] In some embodiments, the microneedle device may be retained in the tissue for up to 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 12 minutes, 14 minutes, 16 minutes, 18 minutes, 20 minutes, 22 minutes, 24 minutes, 26 minutes, 28 minutes, or 30 minutes. The residence time of the microneedle in the tissue allows the probe to contact and bind to a biomarker, e.g., a nucleic acid molecule, within the tissue. In some cases, the residence time of the microneedle in the tissue may be optimized for a particular tissue, biomarker, or probe. For example, biomarkers such as RNA biomarkers may begin to degrade after a certain period of time; therefore, a residence time long enough to allow binding but short enough to minimize degradation is preferred. In some cases, a residence time of about 1 minute to about 10 minutes may be preferred for RNA biomarkers. In some cases, a residence time of less than 5 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes may be preferred for RNA biomarkers. In some cases, a residence time of 10 minutes or less may be preferred for RNA biomarkers. In some cases, a residence time of about 2 minutes to about 9 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 3 minutes to about 8 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 4 minutes to about 7 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes to about 6 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes to about 7 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes to about 8 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes to about 9 minutes may be preferred for RNA biomarkers. In some cases, a residence time of about 5 minutes to about 10 minutes may be preferred for RNA biomarkers.
[0100] In some cases, the optimal residence time of the microneedle in the tissue is determined by the cycle threshold (Ct) for detection of the target biomarker. In some cases, for RNA biomarkers, the Ct is at least about 5 minutes. In some cases, for RNA biomarkers, the Ct of a sample collected after a 10-minute residence time is higher than the Ct of a sample collected after a 5-minute residence time. In some cases, an increase in Ct from the minimum Ct indicates that sample degradation may be occurring.
[0101] In some cases, optimal residence times produce high-quality biomarker samples. In some cases, for RNA biomarkers, the quality of an RNA sample is determined by the ratio of larger RNA fragments (e.g., RNA fragments containing about 700 bases or more) contained in the RNA sample to smaller RNA fragments (e.g., fragments containing about 150 bases to about 200 bases) contained in the RNA sample. In some cases, residence times of 10 minutes or less produce RNA samples that contain a population of large RNA fragments, e.g., RNA fragments containing about 700 bases or more, and a population of small RNA fragments, e.g., fragments containing about 150 bases to about 200 bases, where the ratio of the population of large RNA fragments, e.g., RNA fragments containing about 700 bases or more, to the small RNA fragments, e.g., fragments containing about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 9 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 8 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 7 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1.In some cases, a residence time of 6 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 5 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 4 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of 3 minutes or less produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1. In some cases, a residence time of about 5 minutes produces an RNA sample that includes a population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, and a population of small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, wherein the ratio of the population of large RNA fragments, e.g., RNA fragments comprising about 700 bases or more, to the small RNA fragments, e.g., fragments comprising about 150 bases to about 200 bases, is greater than 1.
[0102] In some embodiments, the probes are allowed time to contact and bind to the biomarkers, and then the device is removed from the tissue. Removal of the microneedles from the tissue can generate shear pressure that removes non-specifically bound contaminants from the microneedles. In some cases, contaminants include any compounds not intended for further genomic analysis.
[0103] In some embodiments, once removed from the skin, the device and extracted RNA biomarkers can be placed in a storage buffer, transport buffer, or analysis buffer. The device and extracted RNA biomarkers can be stored at -80°C, -20°C, -4°C, 4°C, or room temperature. Alternatively, the device can be placed in a buffer to dissociate the extracted RNA biomarkers from the device, and the extracted RNA biomarkers can be stored at -80°C, -20°C, -4°C, 4°C, or room temperature. The extracted RNA biomarkers (with or without the device) can be sent to a laboratory for further analysis.
[0104] In some embodiments, the present disclosure provides a method for preparing a sample for genome or transcriptome analysis. The method may include contacting a device of the present disclosure with a subject's skin, extracting nucleic acid biomarkers from the skin onto the device, and washing the nucleic acid biomarkers from the device to generate a sample solution. The nucleic acids in the sample solution may be analyzed by polymerase chain reaction. In some cases, the extracted nucleic acids in the sample solution may be amplified and analyzed by next-generation sequencing (NGS). NGS of the extracted mRNA may allow for the determination of gene expression in the contacted skin of the subject.
[0105] In some embodiments, the present disclosure provides a method for determining whether a subject's skin lesions respond to an autoimmune therapeutic drug. For example, the present disclosure provides a method for preparing a biological sample and identifying one or more therapeutic drugs for an autoimmune disease in a subject, the method comprising: contacting the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to solid microneedles; and applying pressure to the microneedle device so that the microneedle device penetrates the subject's skin. The ribonucleic acid (RNA) molecules extracted from the subject can be obtained by removing the microneedle device from the subject's skin. High-throughput sequencing can be performed on the extracted RNA molecules to generate one or more sequence reads for the subject, which can be aligned with a known signature of sequence reads, and the known signature of sequence reads is associated with a positive response to an autoimmune disease therapeutic agent, thereby obtaining aligned sequence reads, and applying a trained algorithm to the aligned sequence reads to classify the subject as having a 50%, 60%, 70%, 80%, or 90% or higher probability of responding positively to the autoimmune disease therapeutic agent. In some cases, the trained algorithm has a positive predictive value of 50%, 60%, 70%, 80%, or 90% or a negative predictive value of 50%, 60%, 70%, 80%, or 90% or higher. The autoimmune disease therapeutic agent can be an IL-17-mediated treatment, an IL-23-mediated treatment, a TNFα-mediated treatment, or a combination thereof. The method can include extracting and sequencing mRNA as described above, and using a trained algorithm to compare the gene signature of the lesion with known gene expression signatures, or using a trained algorithm to analyze the gene signature of the lesion.In some cases, the trained algorithm can have a positive predictive value of more than 50% or a negative predictive value of more than 50% to predict a positive response to an autoimmune disease therapeutic drug with a probability of more than 50%.By comparing gene expression signatures, contact skin lesions can be classified as likely to respond to treatment that is either IL-17-mediated, IL-23-mediated, TNFα-mediated, or a combination thereof. Examples of autoimmune disease therapeutics include etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, galcumab, tildrakizumab, and risankizumab.
[0106] In some embodiments, the present disclosure provides a method for determining the likelihood that a subject with an autoimmune disease will respond to a therapeutic drug for the autoimmune disease, the method comprising: obtaining a biological sample from the subject; extracting one or more nucleic acid molecules from the biological sample; performing high-throughput sequencing on the nucleic acid molecules to generate one or more sequence reads for the subject; and performing genomic analysis on the sequence reads. The genomic analysis may include determining expression levels of genes encoded by the sequence reads; comparing the expression levels with known positive response gene signatures specific to the treatment of the autoimmune disease; and generating a treatment score from the comparison, the treatment score being specific to the response to the treatment in the patient.
[0107] In some embodiments, the present disclosure provides a method for treating a skin lesion of a subject, comprising: contacting the skin lesion with a device described herein, extracting mRNA from the skin lesion, determining a gene expression signature using NGS, comparing the signature with a known signature or using a trained algorithm to select a treatment for the subject, and administering the selected treatment to the subject. In some cases, selecting a treatment comprises comparing the expression level of a known positive response gene signature specific to the treatment of an autoimmune disease.
[0108] The present disclosure provides non-invasive and / or minimally invasive devices, methods, and systems that provide subject-specific data sets for disease diagnosis or guided clinical intervention. Microneedle devices, methods, and systems using the same are further described herein. For example, the methods of the present invention described herein may, in some embodiments, include determining gene expression profiles, accurate classification of a disease or condition, prospective guided therapy and / or clinical intervention for a disease or condition, retrospective analysis and modeling of past treatments, identifying activated pathways of a disease or condition, or any combination thereof for one or more subjects. The microneedle devices described herein may provide accurate, minimally, and / or non-invasive sample collection that can be used in downstream analysis as described elsewhere herein, particularly in the aforementioned methods. Thus, the methods of the present disclosure are useful for providing a means for personalized medicine, where treatment is tailored to a subject based on the characteristics of the subject's disease (e.g., the gene expression profile of a subject suffering from a disease).
[0109] Generally, microneedle devices can facilitate the collection of a subject's biological sample in situ for further analysis. In some cases, the microneedle device may include one or more microneedle features configured to puncture the subject's skin or mucosa. In some cases, the mucosa may include oral mucosa, ocular mucosa, or any combination thereof. When multiple microneedles are present, the device may include a planar substrate supporting the microneedles. The substrate can be made of the same material as the microneedles. The substrate can also be made of a different material. In some cases, the microneedles may further include probes attached to the microneedles. These probes can be configured to bind to one or more biomarkers in the subject's sample or tissue (e.g., skin) in a manner that allows for extraction of the biomarkers for further analysis. The extracted biomarkers can be analyzed alone or in combination (e.g., to generate a gene signature or gene expression profile) to provide a diagnosis or prediction of the subject's response to a drug or other therapeutic treatment.
[0110] Treating a subject for mild, moderate, or severe forms of skin disease In some cases, a known treatment for a known disease may not be effective for a particular form of the disease compared to alternative forms of the same disease.The difference between disease forms may result from the different gene signatures from each particular form.In some embodiments, the methods described herein can provide targeted, specialized, individualized, or otherwise highly effective treatment or treatment recommendations for subjects suffering from a particular form of a known disease.
[0111] In some embodiments, the present disclosure provides a method for determining whether a mild, moderate, or severe form of a skin disease in a subject suffering therefrom will respond to a recommended treatment (600), as seen in Figure 6. In some cases, a method for determining whether a skin disease in a subject suffering therefrom will respond to a recommended treatment may include (a) obtaining ribonucleic acid (RNA) biomarkers (described elsewhere herein) (602) from the subject, (b) determining the likelihood that the skin disease will respond to a recommended treatment (604), wherein the recommended treatment comprises an overall efficacy rate of 50% or less for known forms of the skin disease (604), and (c) treating the subject with the recommended treatment (606).
[0112] In some cases, the determining step (i.e., step (b) above) may further include: (i) performing high-throughput sequencing on the RNA biomarker to generate one or more sequence reads for the subject; (ii) aligning the one or more sequence reads for the subject with a known signature of sequence reads, where the known signature of sequence reads is associated with a positive response to the recommended treatment, thereby obtaining aligned sequence reads; (iii) applying a trained algorithm to the aligned sequence reads to classify the subject as having a greater than 50% likelihood of responding positively to the recommended treatment, wherein the trained algorithm comprises a positive predictive value greater than 50% for predicting a greater than 50% likelihood of a positive response to the recommended treatment. In some cases, the RNA biomarker may comprise an RNA molecule. In some examples, the RNA biomarker is transcribed from one or more of the following genes listed in Table 6, Table 12, or Table 13:
[0113] In some embodiments, the trained algorithm may further include a negative predictive value greater than 50% for predicting a greater than 50% likelihood of a positive response to a recommended treatment. In some cases, the positive predictive value may be greater than 50%, 60%, 70%, 80%, or 90%. In some examples, the negative predictive value may be 50%, 60%, 70%, 80%, or 90% or greater.
[0114] In some embodiments, the recommended treatment may include one or more autoimmune therapeutic agents for the autoimmune disease or condition. In some cases, the autoimmune disease or condition may be psoriasis. In some examples, the recommended treatment may include etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, galcumab, tildrakizumab, risankizumab, or any combination thereof.
[0115] Treatment recommendations based on positive predictive value In some cases, one or more subjects suffering from the same disease or condition may respond to a treatment with varying efficacy. In some embodiments, efficacy may include responders, non-responders, or adverse responders. In particular, genetic variation among subjects suffering from the same disease or condition may further stratify the varying efficacy of treatments intended to broadly treat general forms of the disease or condition. Aspects of the disclosure provided herein include, in some embodiments, methods of preparing a biological sample and identifying one or more therapeutic agents to effectively tailor treatment to specific genetic variants (608) of a disease or condition of interest, as seen in FIG. 6B.
[0116] In some embodiments, the present disclosure provides a method for treating or recommending treatment for a subject with an autoimmune disease of the skin (e.g., psoriasis), comprising collecting a sample containing RNA from the subject. Such collection of an RNA sample may involve the use of a microneedle device, or may involve lysing a tissue biopsy or cell sample and extracting nucleic acid (e.g., RNA) using an RNA extraction protocol. In some cases, the subject has not been administered an autoimmune therapeutic agent before the sample is collected. For example, in some embodiments, the subject has not been administered an autoimmune therapeutic agent more than 1, 2, 3, 4, 5, 6, 7, 10, 15, or 20 days before the sample is collected from the subject. In some cases, the method further comprises determining the expression level of at least one gene based on RNA; predicting that the subject with skin autoimmune disease will respond to an autoimmune therapeutic agent based on the expression level of at least one gene with a positive predictive value of more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95%; and / or treating the subject with an autoimmune therapeutic agent based on the prediction.In some cases, the positive predictive value is determined using a cohort of a certain size.For example, the method can have the positive predictive value provided herein when evaluated in a cohort of more than 5, 10, 25, 50, 100, 150, 200, 250, 500, or 1000 patients.
[0117] In some embodiments, the present disclosure provides a method for determining whether a subject's skin lesion responds to an autoimmune therapeutic agent, comprising collecting a sample containing RNA derived from the skin from the subject. Such collection of an RNA sample may involve the use of a microneedle device, or may involve dissolving a tissue biopsy or cell sample and extracting nucleic acid (e.g., RNA) using an RNA extraction protocol. In some cases, the subject has not been administered an autoimmune therapeutic agent before the sample is collected. For example, in some embodiments, the subject has not been administered an autoimmune therapeutic agent more than 1, 2, 3, 4, 5, 6, 7, 10, 15, or 20 days before the sample is collected from the subject. In some cases, the method further comprises converting the RNA into cDNA and determining the expression level of at least one gene based on the cDNA. In some cases, the method further comprises predicting that the subject with skin lesions will respond to an autoimmune therapeutic agent based on the expression level of at least one gene with a positive predictive value of more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, or more than 95%, and / or treating the subject with an autoimmune therapeutic agent based on the prediction.In some cases, the positive predictive value is determined using a cohort of a certain size.For example, the method can have the positive predictive value provided herein when evaluated in a cohort of more than 5, 10, 25, 50, 100, 150, 200, 250, 500, or 1000 patients.
[0118] In some embodiments, the present disclosure provides a method for determining whether a subject's skin lesion will respond to an autoimmune disease therapeutic agent, the method comprising piercing the subject's skin with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to the microneedles. RNA molecules are obtained from the subject by removing the microneedle device from the subject's skin. In some cases, high-throughput sequencing is performed on the RNA molecules to generate sequence reads. The sequence reads are aligned with a sequence read signature associated with a positive response to the autoimmune disease therapeutic agent to obtain aligned sequence reads. A trained algorithm is applied to the aligned sequence reads, the trained algorithm having a positive predictive value of greater than 70%, 80%, 85%, 90%, or 95% for predicting response to the autoimmune disease therapeutic agent. In some cases, the aligned sequence reads are used to determine the expression level of at least one RNA molecule, and a trained algorithm is applied to the expression level of the at least one RNA molecule, the trained algorithm predicting whether the subject with the skin lesion will respond to an IL-17-mediated treatment, an IL-23-mediated treatment, a TNFα-mediated treatment, or any combination thereof. In some cases, high-throughput sequencing is carried out on RNA biomarkers to generate one or more sequence reads for subject.One or more sequence reads are aligned with known signatures of sequence reads, and the known signatures of sequence reads are associated with a positive response to recommended treatment, thereby obtaining aligned sequence reads.Subject is classified as having a possibility of positive response to recommended treatment by applying a trained algorithm to aligned sequence reads, and the trained algorithm comprises a positive predictive value of more than 50%, 60%, 70%, 80%, 85%, 90% or 95% for predicting a positive response to recommended treatment.In some cases, the trained algorithm also has a negative predictive value of more than 50%, 60%, 70%, 80%, 85%, 90% or 95%.In some cases, the recommended treatment includes one or more autoimmune therapeutic agents for the autoimmune disease or condition, including, for example, etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, galcumab, tildrakizumab, and risankizumab. In some cases, the autoimmune disease or condition is psoriasis, acne, atopic dermatitis (i.e., eczema), Raynaud's phenomenon, rosacea, skin cancer (e.g., basal cell carcinoma, squamous cell carcinoma, and melanoma), or vitiligo.
[0119] In some embodiments, the disclosure provides methods for determining whether a subject with an autoimmune disorder of the skin will respond to an autoimmune therapeutic agent, comprising extracting mRNA from the skin of the subject, sequencing the mRNA from the skin of the subject, and predicting whether the subject with the autoimmune disorder will respond to etanercept, adalimumab, infliximab, certolizumab, secukinumab, ixekizumab, broadalumab, glualcumab, tildrakizumab, and risankizumab with a positive predictive value of greater than 50%, 60%, 70%, 80%, 85%, 90%, or 95%.
[0120] In some cases, the at least one gene is at least one gene from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least two genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least three genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least four genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least five genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least six genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least 10 genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least 15 genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least 20 genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least 25 genes from Table 6, Table 12, and / or Table 13. In some cases, the at least one gene is at least 50 genes from Table 6, Table 12, and / or Table 13.
[0121] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CNFN, CTSC, GBAP1, CRABP2, PCDH7, PPIG, RAB31, C3, and EGR. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CNFN, CTSC, GBAP1, CRABP2, PCDH7, and PPIG. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of PCDH7, PPIG, RAB31, C3, and EGR.
[0122] In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of CNFN, CTSC, GBAP1, and CRABP2. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PPIG, RAB31, C3, and EGR. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PCDH7, PPIG, RAB31, and C3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of GBAP1, CRABP2, PCDH7, and PPIG.
[0123] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of SERPINB3, SERPINB4, S100A7A, PI3, KRT6A, LCN2, DEFB4A, DEFB4B, SPRR1A, IL36G, MX1, IFI27, CD36, CD24, and IL4R. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of KRT6A, SPRR1A, CD36, IL4R, LCN2, and IFI27. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of CD36, IL4R, S100A7A, SERPINB4, MX1, and SERPINB3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of LCN2, IFI27, DEFB4A, IL36G, CD24, and PI3.
[0124] In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of IL4R, LCN2, and IFI27. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PI3, IFI27, and SERPINB3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of IL4R, S100A7A, and MX1. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of CD36, LCN2, and SERPINB4.
[0125] In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of MTC01P12, MTATP6P1, CLSTN1, PDPN, LDLRAD2, and GSTM3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of AL158847.1, DAD1, LDLRAD2, ZNF395, MGMT, and AL136982.4. In some cases, the atorbaston gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of NREP, PPIF, PRIM1, AL136982.5, MTATP6P1, and SMPD3. In some cases, the at least one gene is at least one gene, two genes, three genes, four genes, five genes, or six genes from the group consisting of PDPN, TXNRD1, GSTM3, GPSM1, GLRX, and USP2.
[0126] In some cases, the atroyston genes are at least one gene, two genes, or three genes from the group consisting of MTCOIPI2, CLSTN1, and GSTM3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of NREP, PPIF, and PRIM1. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of AL136982.5, MTATP6P1, and SMPD3. In some cases, the at least one gene is at least one gene, two genes, or three genes from the group consisting of PDPN, TXNRD1, and GSTM3.
[0127] In some cases, the genes used to detect response to treatment may be involved in a common pathway, such as the IL-17-mediated pathway, the TNF-α pathway, or the IL-23 pathway. In some cases, the atorbaston gene includes at least 2, 3, 4, 5, 6, 7, 10, 15, or 20 genes that do not share a common upstream regulator or a common pathway. In some cases, the genes have some relationship to the recommended treatment, for example, the genes may be involved in a particular pathway (e.g., the IL-17, IL-23, or TNF-alpha-mediated pathway). In some cases, at least one gene has no known relationship to the recommended treatment. For example, the genes used to evaluate response to a particular therapeutic treatment may not be involved in the pathway targeted by the therapeutic. In some cases, the autoimmune therapeutic is an IL-17-mediated treatment, and the attrimer 1 gene includes at least one gene that is not involved in an IL-17-mediated pathway. In some cases, the autoimmune therapeutic agent is an IL-23 mediated treatment and the at least one gene includes at least one gene that is not involved in an IL-23 mediated pathway. In some cases, the autoimmune therapeutic agent is a TNF-α mediated treatment and the at least one gene includes an atrhyston gene that is not involved in a TNF-α mediated pathway.
[0128] In some cases, a trained algorithm is applied to the expression level of at least one gene to predict the likelihood that a subject will respond to a therapeutic drug. In some cases, the algorithm is trained using samples from patients who have been administered a single type of drug. For example, the patient has been administered IL-17-mediated treatment, TNF-alpha-mediated treatment, or IL-23-mediated treatment.
[0129] In some cases, the method includes the use of a microneedle device. In some cases, the method of preparing a biological sample and identifying one or more therapeutic agents includes (a) contacting the skin of the subject with a microneedle device (610), the microneedle device comprising one or more nucleic acid probes attached to the microneedles, as described elsewhere herein; (b) applying pressure to the microneedle device (612) such that the microneedle device penetrates the skin of the subject; (c) obtaining extracted RNA molecules from the subject by removing the microneedle device from the skin of the subject (614); and (d) performing high-throughput sequencing on the extracted RNA molecules to generate one or more sequence reads for the subject. The method may include step (616), (e) aligning one or more sequence reads for the subject with a known signature of sequence reads, where the known signature of sequence reads is associated with a positive response to one or more therapeutic agents, thereby obtaining aligned sequence reads (618), and classifying the subject as having a likelihood of responding positively to one or more therapeutic agents by applying a trained algorithm to the aligned sequence reads (620), where the trained algorithm has a positive predictive value greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, or greater than 95%. In some embodiments, the method of preparing a biological sample and identifying one or more therapeutic agents may further include administering one or more therapeutic agents to the subject. In some examples, the autoimmune disease or condition is psoriasis.
[0130] In some cases, the subject has at least 8, at least 9, at least 10, or at least 15 PASIs. In some cases, the subject has at least 8 PASIs and at least a PASI 75, 80, 90, 95, or 100 after treatment with the recommended drug. In some cases, the subject has at least 10 PASIs and a PASI 75, 80, 90, 95, or 100 after treatment. In some embodiments, the trained algorithm may further include a negative predictive value greater than 50% for predicting a greater than 50% likelihood of a positive response to one or more therapeutic agents. In some cases, the positive predictive value may be greater than 50%, 60%, 70%, 80%, or 90%. In some examples, the negative predictive value may be 50%, 60%, 70%, 80%, or 90% or greater. In some embodiments, the extracted RNA molecules may be transcribed from one or more of the following genes listed in Table 6, Table 12, or Table 13: In some embodiments, the recommended treatment may include one or more autoimmune therapeutic agents for the autoimmune disease or condition. In some cases, the autoimmune disease or condition may be psoriasis. In some examples, the recommended treatment may include etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, galcumab, tildrakizumab, risankizumab, or any combination thereof.
[0131] In some cases, variability in gene expression between one or more subjects may predict responsiveness to a particular treatment for a disease or condition, particularly psoriasis. Aspects of the invention disclosed herein, in some embodiments, provide a method for determining responsiveness to a disease or condition treatment in a subject suffering from a disease or condition. In some embodiments, the method may further include recommending additional treatment specific to the score. In some cases, the method may further include administering a treatment or additional treatment to the subject. In some cases, the one or more nucleic acid molecules may include a deoxyribonucleic acid (DNA) molecule. In some cases, the one or more nucleic acid molecules include an RNA molecule. In some cases, the RNA molecule may include a messenger RNA (mRNA) molecule.
[0132] In some embodiments, the disease or condition can be an autoimmune disease. In some cases, the autoimmune disease can be psoriasis.
[0133] Determining mild, moderate, or severe forms of a known disease or illness In some cases, particular forms of a disease (e.g., severe, moderate, normal) may comprise different gene signatures. Certain known treatments for a known disease or condition may be less effective for a particular form of the disease compared to alternative forms of the same disease. In some cases, the method may further include recommending a treatment specific to the score. In some cases, the method may further include administering the treatment to the subject. In some cases, the disease or condition may be an autoimmune disease. In some examples, the autoimmune disease may be psoriasis. In some cases, the one or more nucleic acid molecules may comprise a DNA molecule. In some embodiments, the one or more nucleic acid molecules may comprise an RNA molecule. In some cases, the RNA molecule may comprise an mRNA molecule.
[0134] In some embodiments, the at least five genes from Table 6, Table 12, or Table 13 may include genes associated with one or more pathways. In some cases, the at least five genes from Table 6, Table 12, or Table 13 may include at least two genes associated with activation of one or more pathways.
[0135] Identifying the activation of biological pathways associated with a disease or disorder Aspects of the present disclosure, in some embodiments, provide methods for identifying activation of one or more pathways that may be associated with a disease or disorder in a subject (642), as seen in Figure 6C. In some embodiments, the method for identifying activation of one or more pathways that may be associated with a disease or disorder in a subject includes the steps of: (a) contacting the skin of the subject with a microneedle device, the microneedle device comprising one or more nucleic acid probes attached to microneedles (644); (b) applying pressure to the microneedle device such that the microneedle device penetrates the skin of the subject (646); (c) obtaining extracted RNA molecules from the subject by removing the microneedle device from the skin of the subject (648); and (d) performing high-throughput sequencing on the extracted RNA molecules to generate one or more sequence reads for the subject (650). (e) aligning one or more sequence reads for the subject with a known signature of sequence reads, wherein the known signature of sequence reads may be associated with activation of one or more pathways associated with a disease or condition (652), and (f) classifying the subject as having a greater than 50% likelihood of developing a disease or condition associated with activation of one or more pathways by applying a trained algorithm to the aligned sequence reads, wherein the trained algorithm has a greater than 50% positive predictive value or a greater than 50% negative predictive value for predicting a greater than 50% likelihood of developing a disease associated with activation of one or more pathways (654). In some cases, the method may further include recommending a treatment specific to activation of one or more pathways. In some cases, the method may further include administering a treatment specific to activation of one or more pathways to the subject. In some cases, the microneedle may be a solid microneedle.
[0136] In some embodiments, the trained algorithm may further include a negative predictive value of greater than 50% for predicting a greater than 50% likelihood of developing a disease or disorder associated with activation of one or more pathways. In some cases, the positive predictive value may be greater than 50%, 60%, 70%, 80%, or 90%. In some examples, the negative predictive value may be 50%, 60%, 70%, 80%, or 90% or greater.
[0137] In some embodiments, the disease or condition may be an autoimmune disease or condition. In some cases, the autoimmune disease or condition may be psoriasis. In some embodiments, the extracted RNA molecules may be transcribed from one or more genes, including at least one gene associated with activation of one or more pathways. In some cases, the one or more genes may include at least two genes associated with activation of one or more pathways. In some cases, the one or more genes may include any one of the genes listed in Table 6, Table 12, or Table 13.
[0138] As used herein, the term "subject" refers to any animal, including mammals and non-mammals, e.g., humans, non-human primates (e.g., rhesus monkeys, crab-eating macaques, stump-tailed macaques, pig-tailed macaques, squirrel monkeys, domestic monkeys, baboons, chimpanzees, marmosets, and spider monkeys, etc.), rodents (e.g., mice, rats, guinea pigs, etc.), dogs, cats, pigs, etc. In some cases, the subject is a human subject.
[0139] In some embodiments, the subject may be experiencing or have symptoms of a skin disease. Examples of skin diseases that can be detected and / or treated by the methods and devices provided herein include psoriasis, acne, atopic dermatitis (i.e., eczema), Raynaud's phenomenon, rosacea, skin cancer (e.g., basal cell carcinoma, squamous cell carcinoma, and melanoma), and vitiligo. In some cases, the subject may have or have symptoms of one or more skin diseases, such as psoriasis and atopic dermatitis. In some cases, the subject may experience different degrees of skin disease, such as mild, moderate, severe, and very severe. Examples of psoriasis symptoms include red patches of skin covered with thick, silvery scales, small scaling spots, dry, cracked skin that may bleed or itch, itching, burning or pain, thick, pitted, or raised nails, swollen, stiff joints, etc.
[0140] Psoriasis Area and Severity Index (PASI) score The Psoriasis Area and Severity Index (PASI) score is typically used to measure the discoloration, thickness, scaling, and coverage of these plaques. Caregivers (e.g., physicians, nurses, nurse practitioners, physician assistants, etc.) can use the PASI score to measure the severity and extent of psoriasis and monitor the effectiveness of psoriasis treatment. The use of the tool also allows caregivers to monitor disease progression and evaluate the effectiveness of treatment.
[0141] Scoring involves rating psoriasis symptoms from no severity to very severe disease and estimating the percentage of the body they affect. Researchers also use the PASI score to determine the effectiveness of psoriasis medications in clinical trials.
[0142] Absolute PASI scores range from 0 to 72, with higher scores indicating greater psoriasis severity. A score of 0 indicates no psoriasis, while a score higher than 10 suggests severe psoriasis. The scoring system includes a section for intensity and a section for body coverage. The intensity section of the score measures 1) discoloration (i.e., redness), 2) thickness, and 3) scaling. The area section indicates the extent to which psoriasis affects 1) the head and neck, 2) upper extremities, 3) trunk, and 4) lower extremities.
[0143] The PASI score can be calculated as follows:
[0144] [Table 1]
[0145] Clinical researchers often use PASI percentage response rates to indicate treatment results. For example, PASI 75 means that a person's PASI score has decreased by 75% from baseline, indicating a significant improvement in disease. The traditional treatment goal has been to achieve PASI 75. However, PASI 90 or PASI 100 (i.e., a 90% or 100% reduction in PASI score, respectively) are more desirable.
[0146] In some cases, the subject provided herein has a PASI of at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 15. In some examples, the subject has moderate to severe psoriasis and a baseline PASI of 10 or more. In some cases, the method provided herein provides a prediction of whether the subject will respond to a specific treatment. In some cases, after being treated with the recommended treatment, the subject responds to the treatment and has a decrease in PASI score. In some cases, the subject's response to the treatment can be a specific response at 16 weeks after treatment, such as PASI60 at 16 weeks, PASI75 at 16 weeks, PASI80 at 16 weeks, PASI80 at 16 weeks, PASI90 at 16 weeks, PASI95 at 16 weeks, PASI99 at 16 weeks, or PASI100 at 16 weeks. In some cases, the subject's response to the treatment may be a particular response at 12 weeks after treatment, such as PASI60 at week 12, PASI75 at week 12, PASI80 at week 12, PASI80 at week 12, PASI90 at week 12, PASI95 at week 12, PASI99 at week 12, or PASI100 at week 12. In some cases, the subject's response to the treatment is a response at 8 weeks after treatment, such as PASI60 at week 8, PASI75 at week 8, PASI80 at week 8, PASI80 at week 8, PASI90 at week 8, PASI95 at week 8, PASI99 at week 8, or PASI100 at week 8. In some cases, the subject's response to treatment is a response at week 4 after treatment, such as PASI 60 at week 4, PASI 75 at week 4, PASI 80 at week 4, PASI 80 at week 4, PASI 90 at week 4, PASI 95 at week 4, PASI 99 at week 4, or PASI 100 at week 4. In some embodiments, the subject's response to treatment is assessed at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks after treatment.In some embodiments, the subject's response to treatment is assessed up to 2 weeks, up to 3 weeks, up to 4 weeks, up to 8 weeks, up to 12 weeks, up to 16 weeks, up to 20 weeks, up to 24 weeks, or up to 50 weeks after treatment. For example, the subject's response to treatment may, in some embodiments, be assessed 8-12 weeks after treatment, 4-12 weeks after treatment, and / or 8-16 weeks after treatment. In some embodiments, the patient's PASI response may be at least PASI 60, at least PASI 70, at least PASI 80, at least PASI 90, at least PASI 95, at least PASI 99, or PASI 100 over any period after treatment.
[0147] Sample preparation Nucleic acids may be extracted from a sample using the microneedle devices described herein, or may be extracted directly from a sample (e.g., a biopsy sample) using extraction methods other than those involving the use of a microneedle device. Types of nucleic acids that can be extracted include any nucleic acid molecule encoding genetic information, including, for example, messenger RNA (mRNA), microRNA, DNA (e.g., nuclear DNA or mitochondrial DNA), a mixture of mRNA and DNA, short RNA, isolated RNA, and isolated DNA. Biopsy samples that can be used for nucleic acid extraction can include tissue removed from any part of the body, for example, from the surface of the body (e.g., skin, hair, scalp, superficial skin, nails, skin debris, hair follicles) or from the inside of the body (e.g., brain, heart, lung, pancreas, kidney, liver, intestine, muscle, connective tissue, bone, cartilage, or blood). Biopsy samples can be obtained invasively, non-invasively, or minimally invasively. In some cases, biopsy samples are obtained from one or more active lesions, dormant lesions, or normal tissue.
[0148] In some cases, once removed from the skin, the device and extracted RNA biomarkers may be placed in a storage buffer, transport buffer, or analysis buffer. The device and extracted RNA biomarkers may be stored at -80°C, -20°C, -4°C, 4°C, or room temperature. Alternatively, the device may be placed in a buffer to dissociate the extracted RNA biomarkers from the device, and the extracted RNA biomarkers may be stored at -80°C, -20°C, -4°C, 4°C, or room temperature. The extracted RNA biomarkers (with or without the device) may be sent to a laboratory for further analysis.
[0149] In some cases, DNA is sequenced using nanopore sequencing, which allows single molecules of DNA or RNA to be sequenced without the need for PCR amplification or chemical labeling of the sample. In some cases, extracted nucleic acids of a sample can be amplified and analyzed by next-generation sequencing (NGS), high-throughput sequencing, massively parallel sequencing, or sequencing-by-synthesis. Various sequencing approaches can include, for example, pyrosequencing, sequencing by reversible terminator chemistry, sequencing by ligation mediated by ligase enzymes or phosphor-linked fluorescent nucleotides, or real-time sequencing. Methods for performing genomic analysis can also include microarray methods. In some cases, genomic analysis can be performed in combination with any of the other methods described herein. For example, a sample can be obtained, tested for validity, and divided into aliquots. One or more aliquots can then be used for the cytological analysis of the present invention, one or more aliquots can be used for the gene expression profiling method of the present invention, and one or more aliquots can be used for genomic analysis. It will be further understood that the present invention contemplates that one of skill in the art may desire to perform other analyses on the biological sample not expressly provided herein.
[0150] In some embodiments where the nucleic acid molecule is RNA, the method further comprises converting the captured RNA into DNA (e.g., cDNA) that is readily accessible for sequencing (e.g., sequencing by synthesis or nanopore sequencing). In some cases, an RNeasy Mini kit (Qiagen, Valencia, CA) is used for RNA extraction. RNAase-Free Nase digestion (Qiagen, Valencia, CA) can be used to remove genomic DNA from the RNA preparation. A Taqman kit (Applied Biosystems, Foster City, CA) can be used for reverse transcription. For example, 200 ng of total mRNA was added to 20 μL of reverse transcription reaction, and the mixture was incubated at 25°C for 5 minutes, 48°C for 30 minutes, and then 95°C for 5 minutes. The cDNA was stored at -20°C for further use.
[0151] In some cases, cDNA may be amplified and then sequenced by a commercial vendor (Psomagen, Inc., Rockville, MD) according to standard procedures. Library preparation can be accomplished using the Illumina Nextera DNA Flex kit according to the manufacturer's instructions. The prepared indexed library can be loaded onto a NovaSeq 6000 S4 with a read length of 150 PE for sequencing of 40M reads per sample. During sequencing, the quality score (Q30) can be maintained at a specific level, e.g., above 75%. Once the run is complete, the FASTQ file quality can be checked with FASTQC and trimmed with the Trim_galore program. The trimmed FASTQ can be aligned and mapped to the human reference genome (e.g., GRCh38) using the hisat2 program. In some embodiments, the number of reads is counted for each Ensemble gene ID using the FeatureCounts program and Homo sapiens GRCH38.84.gtf. In some cases, RNA expression analyses are further processed using the Bioconductor package edgeR. Genes may be filtered using filterByExpr before calculating logCPM (counts per million reads). Plots may be made with the ggplot2 and heatmap.2 functions in R. The percent of detected genes may be determined using the ratio of detected genes (>0 counts) to the total number of Ensemble genes.
[0152] Common methods for determining gene expression product levels may include, but are not limited to, one or more of the following: further cytological assays, assays for specific protein or enzyme activity, assays for specific expression products including proteins or RNA or specific RNA splice variants, in situ hybridization, whole-genome or partial-genome expression analysis, microarray hybridization assays, SAGE, enzyme-linked immunoabsorbance assays, mass spectrometry, immunohistochemistry, or blotting. Gene expression product levels can be normalized to internal standards such as total mRNA or the expression levels of specific genes, including, but not limited to, glyceraldehyde-3-phosphate dehydrogenase and ortubulin.
[0153] In some embodiments, microarray analysis begins with extracting and purifying nucleic acid from biological samples using methods known in the art (for example, biopsy or fine needle aspiration).For expression analysis, it may be advantageous to extract and / or purify RNA from DNA.It may also be advantageous to extract and / or purify mRNA from other forms of RNA, such as tRNA and rRNA.
[0154] In some embodiments, the purified nucleic acid may be further labeled with a fluorescent, radionuclide, or chemical label such as biotin or digoxin, for example, by reverse transcription, PCR, ligation, chemical reaction, or other techniques. Labeling can be direct or indirect, which may require a further coupling step. The coupling step can be performed before hybridization, for example, using aminoallyl-UTP and an NHS-amino-reactive dye (such as a cyanine dye), or after hybridization, for example, using biotin and labeled streptavidin. Modified nucleotides (e.g., in a ratio of 1 aaUTP:4 TTP) are enzymatically added at a lower ratio than normal nucleotides, typically 1 for every 60 bases (as measured by a spectrophotometer). The aaDNA can then be purified, for example, using a column or diafiltration device. The aminoallyl group is an amine group on a long linker attached to the nucleobase, which reacts with a reactive label (e.g., a fluorescent dye).
[0155] In some embodiments, the labeled sample is then mixed with a hybridization solution, which may contain SDS, SSC, dextran sulfate, a blocking agent (e.g., COT1 DNA, salmon sperm DNA, calf thymus DNA, polyA or polyT), Denhardts solution, formamine, or a combination thereof. Hybridization probes are DNA or RNA fragments of various lengths used to detect the presence of a nucleotide sequence (DNA target) complementary to the sequence in the probe in a DNA or RNA sample. The probe hybridizes to a single-stranded nucleic acid (DNA or RNA) with a base sequence that allows probe-target base pairing due to complementarity between the probe and target. The labeled probe is first denatured (by heating or alkaline conditions) into a single DNA strand and then hybridized to the target DNA.
[0156] In some embodiments, to detect hybridization of the probe to the target sequence, the probe is tagged (or labeled) with a molecular marker; commonly used markers are 32 The hybridization probes are then visualized using autoradiography or other imaging techniques to detect DNA sequences or RNA transcripts with moderate to high sequence similarity to the probe. Detection of sequences with moderate or high similarity depends on the stringency of the hybridization conditions applied—high stringency, such as high hybridization temperature and low salt content in the hybridization buffer, allows hybridization between highly similar nucleic acid sequences, while lower stringency, such as lower temperature and high salt content, allows hybridization between sequences with lower sequence similarity. Hybridization probes used in DNA microarrays refer to DNA covalently attached to an inert surface, such as a coated glass slide or gene chip, to which a mobile cDNA target is hybridized.
[0157] In some embodiments, the mixture may then be denatured by heat or chemical means and added to a port in the microarray. The holes may then be sealed, and the microarray may be hybridized, for example, in a hybridization oven where the microarray is mixed by rotation, or in a mixer. After overnight hybridization, nonspecific binding may be washed away (e.g., with SDS and SSC). The microarray may then be dried and scanned with a specialized machine in which a laser excites the dye and a detector measures its emission. The image may be overlaid with a template grid, and the intensity of the features (how many pixels make up a feature) may be quantified.
[0158] Various kits can be used for nucleic acid amplification and probe generation in the subject method. Examples of kits that can be used in the present invention include, but are not limited to, the Nugen WT-Ovation FFPE Kit and the cDNA Amplification Kit using the Nugen Exon Module and Frag / Label Module. The NuGEN WT-Ovation™ FFPE System V2 is a whole-transcriptome amplification system that enables comprehensive gene expression analysis of the vast archive of small, degraded RNA derived from FFPE samples. The system consists of reagents and protocols necessary for amplifying as little as 50 ng of total FFPE RNA. Protocols can be used for qPCR, sample acquisition, fragmentation, and labeling. The amplified cDNA can be fragmented and labeled for GeneChip® 3' expression array analysis in less than two hours using NuGEN's FL-Ovation™ cDNA Biotin Module V2. For analysis using Affymetrix GeneChip® Exon and Gene ST arrays, the amplified cDNA can be used with the WT-Ovation Exon module and fragmented and labeled using the FL-Ovation™ cDNA Biotin module V2. For analysis on Agilent arrays, the amplified cDNA may be fragmented and labeled using NuGEN's FL-Ovation™ cDNA Fluorescence module.
[0159] In some embodiments, the Ambion WT Expression Kit can be used. The Ambion WT Expression Kit allows for direct amplification of total RNA without a separate ribosomal RNA (rRNA) depletion step. Using the Ambion® WT Expression Kit, samples as small as 50 ng of total RNA can be analyzed on the Affymetrix® GeneChip® Human, Mouse, and Rat Exon and Gene 1.0 ST Array. In addition to lower input RNA requirements and high concordance between the Affymetrix® method and TaqMan® real-time PCR data, the Ambion® WT Expression Kit offers significant increases in sensitivity. For example, the Ambion® WT Expression Kit can be used to obtain a greater number of probe sets detected above background at the exon level as a result of improved signal-to-noise ratios. The Ambion WT Expression Kit can be used in combination with additional Affymetrix labeling kits.
[0160] In some embodiments, the AmpTec Trinucleotide Nano mRNA Amplification Kit (6299-A15) can be used in this method. The ExpressArt® TRinucleotide mRNA Amplification Nano Kit is suitable for a wide range of input total RNA, from 1 ng to 700 ng. It can be used over one round (input >300 ng total RNA) or two rounds (minimum input 1 ng total RNA), with aRNA yields in the range of >10 pg, depending on the amount of input total RNA and the required yield of aRNA. AmpTec's proprietary TRinucleotide priming technology, combined with selection for rRNA, results in preferential amplification of RNA (independent of universal eukaryotic 3'-poly(A) sequences). This kit can be used in combination with the cDNA conversion kit and the Affymetrix labeling kit.
[0161] In some embodiments, the raw data may then be normalized, for example, by subtracting background intensities and dividing the intensities to equal either the total intensity of the feature on each channel or the intensity of the reference gene, and a t-value for all intensities may be calculated. More sophisticated methods include z-ratios, loess and lowess regression, and RMA (Robust Multichip Analysis) for Affymetrix chips.
[0162] In some cases, polyA-tailed mRNA is captured on a support via hybridization to a polyT DNA capture probe or primer bound to the support surface. The polyT strand is then extended with a reverse transcriptase polymerase to create a double-stranded molecule containing a DNA-RNA duplex. Next, a transposome complex (e.g., Tn5 transposase bound to an adapter sequence and a sequence complementary to the surface amplification primer) is added to the support, which undergoes a transposition reaction with the duplex, tagging it and ligating a DNA adapter oligo to the 5' end of the RNA strand. A strand-displacing polymerase (e.g., Bst polymerase) can then be used to extend the 3' end of the DNA strand, displacing the non-transferred strand of the transposome complex and copying the RNA strand to its 5' DNA chimeric end. In some embodiments, the DNA adapter oligo contains a sequence complementary to an anchor primer on a substrate configured for sequencing. In some embodiments, the DNA adapter oligo contains a sequence complementary to a sequencing primer for sequencing. The double-stranded molecule can then be amplified (e.g., cluster amplified) and sequenced with a sequencing primer. The primer partially comprises an adapter sequence and an upstream adapter sequence. Alternatively, the other end of the molecule (the poly-T end) can be sequenced with a primer that anneals upstream of the poly-T sequence and is extended with natural dATP nucleotides before initiating a cycle of sequencing by synthesis (SBS) chemistry.
[0163] In some cases, the RNA is fragmented and treated with phosphatase. A single-stranded adapter molecule is ligated to the 3' end of each RNA fragment containing the complement of the surface-bound primer. The fragments are then added to a support and captured via hybridization. The hybridized RNA molecules are converted to DNA-RNA duplexes using a reverse transcriptase polymerase. A transposome complex or composition containing a transposase and a P5-bearing ME adapter duplex (i.e., a transposon) is used to tagment the duplex. After extension of the DNA strand to the end by a strand-displacing polymerase, the molecule can be amplified (e.g., cluster amplification) and sequenced.
[0164] Bioinformatics analysis of sequence reads As used herein, positive predictive value (PPV) is the percentage of true positives among all subjects who test positive. It can be calculated as PPV = TP / (TP FP), where TP and FP are the number of true positive and false positive results, respectively.
[0165] As used herein, negative predictive value (NPV) is the proportion of true negatives among all subjects who test negative. It can be calculated as PPV=TN / (TN FN), where TN and FN are the number of true negative and false negative results, respectively.
[0166] An algorithm (Mind.Px) was developed herein to predict response to biologics (anti-IL-17, anti-IL-23) used to treat patients with psoriasis by comparing baseline transcriptomes with clinical response to the biologic drug 12 weeks after initial treatment. Sixty-two responding patients (out of 75) had a change in Psoriasis Area and Severity Index (PASI) of 0.75 or greater, while non-responders had a change in Psoriasis Area and Severity Index (PASI) of -0.2 to 0.75. Cross-validation using linear regression modeling demonstrated a balanced predictive accuracy of 0.71, using PASI75 as the cutoff for assessing classifier performance. A positive predictive value of 0.95 was achieved.
[0167] In some cases, the sequence read from the subject is compared with the sequence read from a positive control or a negative control.The positive control is a subject diagnosed with a disease or condition.The negative control is a healthy person who does not have any symptoms or history of symptoms of a disease or condition.Alternatively, the negative control can be the baseline of the subject before treatment.
[0168] Biologics As used herein, the term "biologic" refers to a pharmaceutical product derived from a living organism (e.g., a human, animal, or microorganism), including recombinant biological products produced by genetic engineering techniques. For example, a biologic may contain cells that produce proteins that control the action of other proteins and cellular processes, genes that control the production of important proteins, modified human hormones, or substances that suppress or activate components of the immune system. In some cases, the biologic is an antibody (e.g., a monoclonal antibody). In some cases, a subject is treated with one or more of the following biologics: tumor necrosis factor inhibitors (e.g., adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol), IL-17 inhibitors (e.g., secukinumab, ixekizumab, and brodalumab), and IL-23 inhibitors (e.g., tildrakizumab, guselkumab, ustekinumab, and risankizumab).
[0169] Whenever the terms "at least," "greater than," or "greater than or equal to" precede the first number in a series of two or more numbers, the terms "at least," "greater than," or "greater than or equal to" apply to each and every number in the series. For example, 1, 2, or 3 or more is equivalent to 1 or more, 2 or more, or 3 or more.
[0170] Whenever the term "less than or equal to," "less than," or "less than or equal to" precedes the first number in a series of two or more numbers, the term "less than or equal to," "less than," or "less than or equal to" applies to each of the numbers in the series. For example, 3, 2, or 1 or less is equivalent to 3 or less, 2 or less, or 1 or less.
[0171] The term "bases" as used herein refers to nucleotides. In some cases, "bases" may refer to base pairs ("bp"), e.g., 1 base equals 1 base pair. As used herein, the terms "bases" and "base pairs" are used interchangeably.
[0172] As used herein, the term "about" means within 10% above or below a given value. For example, "about 10" includes values from 9 to 11, unless otherwise dictated by the context in which the term is used.
[0173] The following examples are provided to further illustrate the advantages and features of the present invention, but are not intended to limit the scope of the invention. While they are typical examples that may be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used. [Example]
[0174] Example 1: Device fabrication The device of the present disclosure is manufactured using injection molding. According to the features disclosed herein, the device is manufactured by injecting a heated (e.g., molten) material, such as a polyolefin resin disclosed herein, into a mold for the device. The mold comprises a plurality of cavities for forming a plurality of microneedles, a cavity for forming an interior containing the plurality of microneedles, and one or more cavities for forming one or more peripheral portions adjacent to the interior. In this device, the width of the interior is smaller than the width of the peripheral portion. The width of the intersection portion is approximately 1:5 in size compared to the width of the peripheral portion.
[0175] As the heated material is injected through the mold, the smaller width of the interior (compared to the periphery) facilitates migration of the heated material into one or more cavities to generate multiple microneedles before generating the interior and periphery.
[0176] The result is a device described herein with uniformly sharp microneedles, with no more than 3% of the microneedles deviating from the average length of the plurality of microneedles by more than about 50 μm (+ / -).
[0177] Example 2 Binding probes to the device of Example 1 The microneedles of the device of Example 1 are plasma treated as described herein: the device, or a portion thereof, is placed in a plasma vacuum chamber, the plasma vacuum chamber is closed to form a sufficient vacuum seal, any existing gas present in the chamber is evacuated, and a plasma treatment gas is pumped into the plasma vacuum chamber to a predetermined pressure, allowing for the generation of a gas plasma.
[0178] The gas plasma reacts with the heated material of the device (eg, the polyolefin resin described herein), making the material more reactive to form covalent bonds with the probes described herein.
[0179] Example 3 Kinetics of mRNA extraction The optimal time for mRNA extraction was determined by placing the microneedle device described herein on the skin of healthy subjects for various periods, then removing the patch from the skin and performing subsequent amplification, cDNA synthesis, and qPCR analysis. The device was placed on the subject for 20 seconds, 1 minute, 5 minutes, and 10 minutes, and cycle threshold (Ct) values were measured for two biomarkers, GAPDH and KRT10, generated from mRNA samples collected from the device at each dwell time. All measurements were performed in triplicate.
[0180] As seen in Table 1, optimal extraction occurs at 5 minutes of residence time in the skin, with degradation beginning to dominate by 10 minutes of skin insertion.
[0181] [Table 2]
[0182] Example 4 Qualification of extracted mRNA To demonstrate the quality of intact mRNA, bioanalyzer QC and qPCR analyses were performed using mRNA extracted from the microneedle device described herein.
[0183] For intact / high-quality mRNA, successful cDNA synthesis and amplification showed clear amplification peaks ranging from approximately 300 to approximately 10,000 bp, with one peak at approximately 1,500 bp (Figure 5A). Quantification of the area under these curves resulted in a corrected area QC ratio of greater than 1 (corrected area of large mRNA fragments (700-20,000 bp) / corrected area of small mRNA fragments (150-200 bp)). In contrast, in partially degraded samples, the amplification peak shifted to smaller fragments of 100-1,000 bp with degraded mRNA (Figure 5B). Furthermore, in fully degraded samples, the peak around 1,500 bp was no longer observed (Figure 5C). Importantly, the corrected area QC ratios were less than 1 in these partially and fully degraded samples. Furthermore, qPCR analysis was performed on these samples. Using a representative gene (B2M), the Ct value from the degraded RNA sample increased from a Ct of 19.25 for the control sample (intact RNA) to 22.70; this 3.45 Ct increase indicated an approximately 11-fold decrease in the amount of mRNA in the degraded sample.
[0184] Example 5 Prospective prediction of individual patient response to TNFα, IL-17, and IL-23 inhibitors The response of patients with psoriatic skin disease to specific drug classes (e.g., TNFα, IL-17i, and IL-23i inhibitors) was prospectively determined prior to administration of these drug classes via a predictive linear classifier modeling approach. To determine patient response, a painless, FDA-registered Class I skin biomarker patch was used to extract each patient's total RNA transcriptome via 5-minute exposure of the patch to the patient's skin. The skin biomarker patch was then treated, and the RNA attached to the patch was extracted and sequenced using next-generation sequencing. The RNA sequencing readouts were then aligned and compared to a database of patients with similar disease-state RNA gene profiles and their respective responsiveness or non-responsiveness to specific drug classes. Comparison of the RNA sequencing readouts to the database with the predictive linear classifier provided a score for the probability that a particular drug or drug class would provide an effective response to treating the disease state.
[0185] Using the previously described methods, the positive predictive value (PPV), sensitivity, and balanced accuracy of predictive linear classifiers were evaluated for the TNFαi (PASI75@W12), IL-17i (PASI75@W12), and IL-23i (PASI150@W12) drug classes. The TNFαi inhibitor drug class was evaluated across a training set of 34 patients and a test set of 15. The PPV, sensitivity, and balanced accuracy obtained for the linear classifier were 89%, 80%, and 80%, respectively. The IL-17i inhibitor drug class was evaluated across a training set of 75 patients and a test set of 6. The PPV, sensitivity, and balanced accuracy obtained for the linear classifier were 100%, 100%, and 100%, respectively. The IL-23i inhibitor drug class was evaluated across a training set of 17 patients and a test set of 17. The PPV, sensitivity, and balanced accuracy obtained for the linear classifier were 90%, 82%, and 83%, respectively. The mean PPV and sensitivity for the three inhibitor drug classes were calculated to be 95% PPV, 87% sensitivity, and 88% specificity.
[0186] Example 6 Machine Learning-Based Tests to Predict Response to Psoriasis Biologics This study was designed to develop and prospectively validate a machine learning-based algorithm capable of predicting patient response to the most common biologic drug classes used in the management of psoriasis patients. This type of tool would allow clinicians to have greater confidence that a given patient will respond to a particular drug class, which could lead to improved health outcomes and reduced healthcare waste.
[0187] Patients were enrolled in one of two observational studies (STAMP studies), in which a skin biomarker patch (DBP) was applied at baseline before drug exposure, followed by clinical assessment 12 weeks after exposure. PASI measurements were performed at baseline and at week 12 to assess clinical response against clinical phenotypes. Responding patients were defined as those who achieved PASI 75 at week 12. Transcriptomes obtained from DBPs were sequenced and analyzed to derive and / or validate classifiers for each biologic class, which were then combined to obtain predicted responses for all three biologic drug classes (IL-23i, IL-17i, and TNFαi).
[0188] A total of 242 psoriasis patients were enrolled in these studies, including 118 patients (49.6%) treated with IL-23i, 79 patients (33.2%) treated with IL-17i, 35 patients (14.7%) treated with TNFαi, and 6 patients (2.5%) treated with IL-12 / 2 3i. The IL-23i predictive classifier was developed from previously enrolled patients and independently validated in later enrolled patients. The IL-17i and TNFαi predictive classifiers were developed using publicly available datasets and independently validated in patients from the STAMP study. In independent validation, the positive predictive values for the three classifiers (IL-23i, IL-17i, and TNFαi) were 93.1%, 92.3%, and 85.7%, respectively. Across the entire cohort, 99.5% of patients were predicted to respond to at least one drug class.
[0189] This study demonstrates the strength of using baseline skin biomarkers and machine learning methods applied to predict psoriasis biologics before drug exposure. Using this test, patients, physicians, and healthcare systems can all realize significant benefits. Precision medicine can be achieved for individual patients, as the majority will have a high probability of responding to their first prescribed biologic. Physicians can prescribe these medications with greater confidence, and healthcare systems will realize lower net costs and a significant reduction in waste by significantly improving initial response rates to expensive biologic therapies.
[0190] Psoriasis is a T-cell-mediated inflammatory skin disease characterized by discrete erythematous plaques and papules with ciliary scaling. Globally, it is a common disease, with approximately 2.8% of the U.S. population, or 7.5 million people, diagnosed with psoriasis. The current treatment paradigm for psoriasis is characterized by topical drug therapy and / or phototherapy for patients with mild to moderate disease and systemic drug therapy for patients classified as moderate to severe disease. The emergence of biologic therapy as one of these systemic agents has revolutionized the management and treatment of psoriasis patients, a direct result of an increased molecular understanding of the disease. Currently, there are 11 approved biologic drugs approved for use in the U.S. for the treatment of psoriasis, with many more in development. However, it is unclear which biologics will be effective for a given patient.
[0191] Disclosed herein is a novel biomarker capture platform that utilizes a skin biomarker patch to capture the entire transcriptome, including mRNA biomarkers, from the epidermis and upper skin. This platform demonstrates excellent compatibility with biopsies and provides a scalable method for minimally invasively accessing skin biomarkers. It is contemplated that this platform will be used in preliminary machine learning classifiers to predict response and non-response to IL-17 and IL-23 inhibitors. Also disclosed herein is the extension of this preliminary study to the development and prospective validation of practical clinical trials to predict patient response to psoriasis biologics for all three drug classes.
[0192] method Skin Biomarker Patch Platform The skin biomarker patches (DBPs) used in this study were prepared and modified as described above and used according to the manufacturer's specifications.
[0193] Recruitment and enrollment of human subjects Data were analyzed from a retrospective and ongoing, observational, multicenter (20 sites), single-arm, open-label, 12-week study, referred to as the STAMP study. The protocols for these studies were approved by the local ethical review committee and adhered to the Declaration of Helsinki and the International Committee for Clinical Research (ICH) Guidelines on Good Clinical Practice (GCP). All treated patients provided written informed consent. The primary objective of the study protocol was to investigate whether transcriptomics could be used, at baseline or during treatment, to aid in the prediction of drug selection and to provide new therapeutic targets for drug development (Table 2). Visits included screening, baseline, weeks 1, 4, 8, and 12. PASI, PGA, and BSA scores were assessed at all visits except the screening visit. Subjects received a skin biomarker patch at all visits except the screening visit. Subjects' medical history, physical examination, and demographic information were collected at screening.
[0194] [Table 3]
[0195] Study population These studies enrolled patients of both sexes who were 18 years of age or older, diagnosed with psoriasis by either a rheumatologist or dermatologist, had at least one identifiable study lesion measuring 2 cm or greater in diameter, and were scheduled for treatment with IL-23 inhibitor (IL-23i), IL-17 inhibitor (IL-17i), or TNFα inhibitor (TNFαi) therapy immediately after enrollment. Exclusion criteria included the use of topical steroids on study lesions within 2 weeks prior to the baseline visit and concurrent use of Plaquenil. All study participants were also instructed to refrain from all topical steroid use throughout the study until the end of study treatment.
[0196] Application of skin biomarker patches A customized spring-loaded applicator was used to apply DBP to the skin. This applicator helped standardize application pressure across subjects and users. The loaded applicator was placed against the skin, and the trigger was pressed to apply the patch to the skin. The patch was then held in place against the skin by a ring of medical tape for 5 minutes. After this, the patch was removed from the subject and immediately placed in a storage buffer (LiCl, Triton X-100, Tris-EDTA) and stored at 4°C until processing.
[0197] Skin biomarker patch-treated skin transcriptomes were processed within 96 hours of collection from the subjects. The applied DBP was washed with chilled 1x PBS and then dried under a stream of nitrogen. mRNA extraction from the patch was performed by applying PCR-grade water (50 pL, 95°C) to the DBP. The patch was then heated at 95°C for 1 minute to elute the bound mRNA from the DBP. This eluted mRNA was then converted to cDNA using the Takara SMART-Seq® Single Cell Kit according to the manufacturer's instructions. The amplified cDNA samples were then stored at 4°C until analysis.
[0198] Next-generation sequencing procedures The amplified cDNA was sequenced by a commercial vendor (Psomagen, Inc., Rockville, MD) according to standard procedures. Library preparation was accomplished using the Illumina Nextera DNA Flex kit according to the manufacturer's instructions. The prepared indexed libraries were then loaded onto a NovaSeq6000S4 with a read length of 150 PE for sequencing 40M reads per sample. The quality score (Q30) was maintained above 75% throughout sequencing. Upon completion of the sequencing run, FASTQ file quality was checked with FASTQC and trimmed with the Trim galore program. The trimmed FASTQ files were aligned and mapped to the human reference genome GRCh38 using the hisat2 program. The number of reads was counted for each Ensemble gene ID using the FeatureCounts program and the Homo sapiens GRCH38.84.gtf. RNA expression analysis was further processed using the Bioconductor package edgeR. Genes were filtered using filterByExpr before calculating logCPM (log counts per million reads) as a measure of gene expression level. LogCPM values were used for downstream classifier construction.
[0199] IL-23 classifier development Five common classifiers were selected and applied to predict responding patients under IL-23 i treatment using the package caret in R. The selected classifiers are frequently used in the medical field to explore predictive or prognostic biomarkers and include glmnet (Lasso and Elastic-Net Regularized Generalized Linear Model), PAM (Nearest Shrunken Centroids), LM (Linear Regression Model), SVM (Support Vector Machine), and RF (Random Forest).
[0200] The five classifiers were compared for their predictive performance using the following experimental design: 1) split the dataset into 10 outer folds; 2) for each fold, preprocess the data for feature selection and select the top 20, 50, or 200 differentially expressed genes (features) using a linear regression model; 3) tune hyperparameters on the training set via 10-fold cross-validation and repeat the process five times; 4) derive a model from the training set based on the selected hyperparameters and apply it to the test set. Performance metrics on the test set were then calculated. This process was repeated five times for each classifier.
[0201] In the STAMP study, the earliest enrolled IL-23i-treated patients were used for IL-23i classifier training. Baseline PASI filters (none, 6, 8, and 10) were applied to explore the effect of disease severity on classifier performance. Classifier training was performed using the machine learning approach described above, and test performance was evaluated using 10-fold cross-validation. Once the desired performance (>85% PPV and >85% sensitivity) was achieved, the IL-23i classifier was locked. IL-23i-treated patients enrolled after classifier lock were used as an independent validation set.
[0202] IL-17 classifier development This paper discloses a list of 17 genes that predicts psoriasis patient response to IL-17i by analyzing publicly available datasets. Briefly, patients with moderate to severe psoriasis (baseline PASI>10) were treated with brodalumab and followed for 12 weeks. PASI measurements were performed at baseline and week 12, and the week 12 PASI75 was used to evaluate patient treatment response. Lesional and non-lesional skin biopsy samples were collected at baseline and week 12. RNA profiling was performed using the Affymetrix microarray platform. Lesion samples collected at baseline were used for predictive biomarker analysis.
[0203] The 17 predictive genes were negatively correlated with patient response to brodalumab. The 17 genes were mapped to 14 Ensemble gene IDs reported in the RNASeq data from the STAMP study. The 14-gene classifier was validated in the STAMP study.
[0204] Development of a TNFαi classifier Publicly available datasets in the NCBI Gene Expression Omnibus (GEO) database (https: / / www.ncbi.nlm.nih.gov / geo / ) and the European Bioinformatics Institute (EMBL-EBI) Big Data database (https: / / www.ebi.ac.uk / ) were used as classifier training datasets. For initial data selection, search terms and transcriptome profiles of biologic-treated psoriasis patients were used to identify either array or sequencing data.
[0205] Supervised predictive biomarker selection was applied to individual training data to filter genes based on the following evaluations: 1) correlation between gene expression and patient response, 2) median gene expression level, 3) gene expression dynamic range, and 4) difference between mean gene expression in responders and mean gene expression in non-responders. The ratio of down- and up-regulated genes in TNFαi responders was used to develop a prediction of TNFαi treatment response.
[0206] Forward Classifier Validation The IL-23i, IL-17i, and TNFαi classifiers were independently validated using patients enrolled in the STAMP study. Each classifier discretely predicted patients as either responders or non-responders to a biological class. Response was defined as achieving PASI 75 at week 12. Cross-tabulations of observed and predicted classes and related statistics were calculated using the confusionMatrix function in the caret package in R.
[0207] (a) Characteristics of the test subject A total of 242 psoriasis patients were enrolled in the STAMP study at the time of data lock (Figure 7), including 38 patients who were still undergoing follow-up. STAMP is a dynamically recruiting study designed to continue enrolling new patients to support psoriasis biomarker research. A variety of demographic and clinical characteristics were observed among study subjects (Table 3). With regard to drug class, 49.6% of patients were treated with IL-23i, 33.2% with IL-17i, 14.7% with TNFαi, and 2.5% with IL-12 / 23i.
[0208] [Table 4]
[0209] Of the 242 patients initially identified for this study, 185 patients completed the study, i.e., both baseline and week 12 PASI scores were collected; 57 patients failed screening, were lost to follow-up, or were still being followed. Baseline DBP samples were collected for 177 of the 185 patients, while 8 patients failed to collect DBP samples. Of this subset, 167 samples passed sequencing data QC metrics and were included in biomarker analysis; 10 (5.4%, 10 / 177) samples failed either sample processing or sequencing data QC.
[0210] The patient response rate was 64.1% for the entire cohort, ranging from 47.6% to 72.5% for the different biologics (Table 4). Patients with a high PASI score (baseline PASI > 8) had a 26.4% higher response rate than patients with a low PASI score across all drug classes.
[0211] [Table 5]
[0212] Patients with high PASI (baseline PASI > 8) were used for the development and validation of the predictive classifier. The IL-23i-treated patient population was divided into two subsets: 17 IL-23i-treated patients were used for training the IL-23i predictive classifier, and the remaining 43 patients were used for prospective validation. All IL-17i and TNFαi patients with high PASI were used for classifier validation.
[0213] (b) Development and performance of the IL-23i classifier on the training set A subset of 17 IL-23i-treated patients with a high PASI score (>8), including nine responders and eight non-responders, was used to train the IL-23i predictive classifier. The best-performing model was built on glmnet using the top 50 features selected by the linear regression model. Test performance was evaluated using 10-fold cross-validation, and the positive predictive value (PPV), sensitivity, and balanced accuracy were 89.7%, 96.3%, and 91.9%, respectively.
[0214] TNFαi data sources and predictive biomarker discovery Four publicly available datasets (Table 5) were identified and used for TNFαi response classifier development. A total of 73 patients were included in these datasets, of which 58 patients had both transcriptome data for predictive biomarker discovery and treatment outcome assessment data. Patient outcomes were assessed by PASI75 or histological response at weeks 12 or 16.
[0215] [Table 6]
[0216] Supervised predictive biomarker selection was applied to four training datasets. Nine genes were determined to be predictive of TNFαi response in at least two datasets (Table 6). The output of the classifier was a TNFαi response prediction score; in this scoring system, the lower the prediction score, the more likely the patient will respond to TNFαi treatment. The classifier performed well on this training set, demonstrating PPV, sensitivity, and balanced accuracy of 78.9%, 43.1%, and 63.7%, respectively (Table 7).
[0217] [Table 7]
[0218] [Table 8]
[0219] Validation of the Mind.Px classifier Patient demographics and disease characteristics of the 95 patients included in the prospective validation can be seen in Table 8. Only patients with a baseline PASI >8 were included in the validation. For the three classifiers, the positive predictive values ranged from 85.7% to 93.1% (Table 9). The correlation between the observed 12-week PASI change and the predicted drug response was evaluated (Figure 8A-C).
[0220] [Table 9]
[0221] [Table 10]
[0222] The same analysis was repeated for 66 patients with moderate to severe disease (i.e., PASI>10), and similar overall study performance was observed in this smaller cohort, with PPVs ranging from 90% to 100% (Table 10).
[0223] [Table 11]
[0224] Patients with a baseline PASI < 8 were also analyzed to determine the performance of the classifiers in patients with milder disease. In this case, the balanced accuracy ranged from 44.4% to 52.8% for the three classifiers, suggesting that the developed classifiers were optimized for patients with moderate to severe psoriasis.
[0225] Response rates predicted by Mind.Px The predicted response rates for patients by all three classifiers (IL-23i, IL-17i, and TNFαi) were evaluated using 195 patients with baseline DBP samples and completed RNASeq sequencing data (Figure 9 and Table 11). Individually, the predicted response rates were 72.3%, 51.7%, and 67.1% for the IL-23i, IL-17i, and TNFαi classifiers, respectively. Importantly, 99.5% (194 / 195) of patients were predicted to respond to at least one of the three drug classes. For all possible combinations of the three drug classes, 17.4% (34 / 195) of patients were predicted to respond to all three drug classes, 56.9% (111 / 195) were predicted to respond to two of the three drug classes, and 25.1% (49 / 195) were predicted to respond to one of the three drug classes.
[0226] [Table 12]
[0227] Demographics of the STAMP Study This analysis included 242 patients, whose demographics, including gender, race, and age, were largely consistent with previous studies (Table 3). Similarly, the average patient in these studies was obese (BMI > 30), and the average age was 48.5 years. Most interestingly, in this study, the majority of patients (86%) were biologic-naive or had not received a biologic within the past 12 weeks. This finding was particularly surprising given that many patients with moderate to severe psoriasis are exposed to biologics; however, analysis of classifier responses in biologic-naive versus biologic-exposed patients showed no difference between the algorithm's predictive value in either of these patient groups.
[0228] Classifier development and validation The final IL-23i classifier was developed and validated using patients enrolled in the STAMP study. A subset of all IL-23i-enrolled patients was used as the training set, and the remaining patients in the cohort were used for classifier validation. Because the training and test sets were derived from the same study using identically processed samples and data, the classifier developed using the training set could be applied to the test set without further normalization.
[0229] The strategy for developing the IL-17i and TNFαi classifiers differed from that for the IL-23i classifier. Because the sample size of IL-17i and TNFαi patients in the STAMP study was smaller than that of IL-23i patients and was not sufficient to separate them into separate training and test sets, publicly available datasets were used to train these two classifiers. It should be noted that the training set from the public data differed significantly from the test set in several aspects, including sample collection method (punch biopsy vs. skin patch), RNA preparation protocol, and transcriptome profiling method (array vs. sequencing-based). Due to these different properties of the training set, the training set was primarily used solely for feature selection. Once predictive genes were identified, a simplified algorithm utilizing gene expression values or ratios of gene expression values was applied as a predictive classifier. Cutoffs were pre-set before validation using percentile data values calculated from the prediction scores of STAMP patients, which allowed for evaluation of classifier performance while minimizing the risk of overfitting.
[0230] Here, PASI75 at week 12 was used as the determinant of patient outcome. In clinical situations where a better response is desired (e.g., PASI90 or PASI100), the classifier could potentially be used to identify this group of patients, with appropriate clinical cutoff adjustments. Further classifier development to definitively identify "super-responders" or "super-non-responders" is ongoing and will be reported in the future.
[0231] All three classifiers were validated for patients with a baseline PASI score >8. However, the predictive value of these classifiers in patients with lower starting PASI scores was limited. This may be because the three classifiers were developed using patients with high PASI scores (>10) as the training set to match the type of patients enrolled in the pivotal clinical studies of each biologic. Milder patients may have different transcriptome biomarkers. Alternatively, the reliability of the response determination scale (PASI75) in patients with low starting PASI scores is low due to a reduced dynamic range of measurement.
[0232] Other clinical variables have previously been used to stratify psoriasis patients or have been associated with poorer treatment outcomes. In particular, BMI and age have been reported to have clinical prognostic value in assessing the response to biologic treatment. The predictive significance of BMI and age as possible orthogonal input variables in classifiers was tested. However, when examining predictive models, adding either variable as a covariate did not result in any improvement in predictive accuracy or positive predictive value.
[0233] The incidence of biomarker-predicted responses revealed an important feature of this study. Only one patient out of 195 patients tested was predicted not to respond to any of the three biologic drug classes. These data are consistent with the widely accepted clinical fact that the treatment and management of psoriasis has changed dramatically since the introduction of biologics, and almost all patients will respond to one of the three classes of biologics. However, a discrepancy was observed between biologic prescribing behavior and the biologic class predicted by the study. Only 14.7% of enrollees in the observational STAMP study were prescribed a TNFαi biologic (49.6% of the patient cohort), yet 67% of the patient population was predicted to respond to this class.
[0234] By combining a skin biomarker patch platform with machine learning methods, we present a practical machine learning-based precision medicine test capable of predicting psoriasis patient response to biologics (TNFαi, IL17i, or IL23i) with a high positive predictive value. Interestingly, when the entire patient cohort was examined, nearly all patients were predicted to respond to at least one biologic class, highlighting the significant efficacy of biologic drugs in the treatment of psoriasis. Baseline biomarkers combined with machine learning algorithm development can be used to prescribe the appropriate biologic for a given patient the first time. This test could lead to improved patient outcomes while also significantly reducing costs for the healthcare system. This test effectively minimizes the trial-and-error approach to biologic treatment for psoriasis, providing physicians, patients, and payers with a powerful tool for personalized medicine in the management of psoriasis patients.
[0235] Example 7. Efficient prediction of response to psoriasis biologics using machine learning classifiers In the United States, psoriasis affects more than 3% of the population, and treatment can cost between $87,585 and $366,645 annually with the most frequently used medications. It typically takes 12 to 16 weeks for a significant clinical response to treatment, and the efficacy of currently available therapies ranges from 30% to 80%, due at least in part to the inability to predict response to a particular treatment regimen.
[0236] The algorithm (Mind.Px) described herein was developed to predict response to biologic drugs (anti-IL-17, anti-IL-23) used to treat patients with psoriasis by comparing baseline transcriptome data with clinical response to the biologic drugs 12 weeks after initial treatment. Sixty-two responding patients (out of 75) had a change in Psoriasis Area and Severity Index (PASI) of 0.75 or greater, while non-responders had a change in Psoriasis Area and Severity Index (PASI) of -0.2 to 0.75. Cross-validation using linear regression modeling demonstrated a balanced predictive accuracy of 0.71 using PASI75 as the cutoff for assessing classifier performance. A positive predictive value of 0.95 was achieved. A total of 17 genes were identified as correlated with patient response to anti-IL-17 biologics. Alternatively, a prospective classifier was constructed using patients treated with anti-IL-23 biologics using the same response criteria (N=17). A total of 27 genes were confirmed for use in this classifier, with a positive predictive value (PPV) across both classifiers of 100%.
[0237] The classifier for biologics prediction primarily utilized orthogonal biomarkers and achieved high PPV. The use of Mind.Px will result in better treatment outcomes in patients with psoriasis and significantly reduce costs to the healthcare system.
[0238] Recruitment and enrollment of human subjects Subjects with active psoriasis and lesions >2 cm in diameter were enrolled. All procedures were approved by an independent institutional review board (Integreview, Austin, TX), and written consent was obtained from all subjects prior to the study. This study was not influenced by statistical significance. For each subject, a oneMindera skin biomarker patch (DBP) was applied to the lesioned skin. Samples were immediately placed in vials containing storage buffer according to the manufacturer's instructions and kept at 4°C until processing. Processing was performed according to the Mind.Px kit instructions.
[0239] Application of skin biomarker patches A customized spring-loaded applicator was used to apply the patch to the skin. This applicator helped standardize the application pressure across subjects and users. The loaded applicator was placed against the skin, and the trigger was pressed to apply the patch to the skin. The patch was then held in place against the skin by a ring of medical tape for 5 minutes. After this, the patch was removed from the subject and immediately placed in a storage buffer (LiCl, Triton X-100, Tris-EDTA) and stored at 4°C until processing.
[0240] Treatment of skin biomarker patches Skin transcriptomes were processed within 72 hours of collection from the subjects. Samples were prepared by washing the applied DBP with chilled 1x PBS and then drying the patch under a stream of nitrogen. The dried DBP was then placed on a heat block pre-set to 95°C for 1 minute, at which point 50 pL of PCR-grade water pre-heated to 95°C was applied to the microneedle array for 1 minute to elute the bound mRNA from the DBP. This eluted mRNA was then converted to cDNA using the Takara SMART-Seq® Single Cell Kit according to the manufacturer's instructions. The amplified cDNA samples were then stored at 4°C until qPCR or NGS analysis.
[0241] Sequencing procedure The amplified cDNA was sequenced according to standard procedures by a commercial supplier (Psomagen, Inc., Rockville, MD). Library preparation was achieved using the Illumina Nextera DNAFlex kit according to the manufacturer's instructions. The prepared indexed libraries were then loaded onto a NovaSeq6000S4 with a read length of 150 PE for sequencing 40M reads per sample. The quality score (Q30) was maintained above 75% throughout sequencing. Upon completion of the run, FASTQ file quality was checked with FASTQC and trimmed with the Trim galore program. The trimmed FASTQs were aligned and mapped to the human reference genome GRCh38 using the hisat2 program. The number of reads was counted for each Ensemble gene ID using the FeatureCounts program and the Homo sapiens GRCH38.84.gtf. RNA expression analysis was further processed using the Bioconductor package edgeR. Genes were filtered using filterB yExpr before calculating logCPM (counts per million reads). Plots were created using the ggplot2 and heatmap.2 functions in R. The percent of detected genes was calculated using the ratio of detected genes (counts >0) to the total number of Ensemble genes.
[0242] Bioinformatics procedures The Mind.Px algorithm was implemented as an R script in the DNAnexus® system (Mountain View, CA), a cloud-based data analysis and management platform for DNA sequencing data. Cutoff points for anti-IL-17 and anti-IL-23 response prediction were defined and implemented in the R script.
[0243] Data were collected from three phase 3 randomized clinical trials: AMAGINE-1, AMAGINE-2, and AMAGINE-3. The endpoint was PASI75 at week 12. Biopsies were taken from the lesional areas. Transcriptome analysis was performed on the biopsies using the Affymetrix platform. A total of 75 patients were treated with rodalumab, including 62 responders (83%) and 12 non-responders (16%). All 17 patients enrolled in the Mindera-sponsored STAMP (Study Through Mindera Patch Application) trial were also included in the analysis. (STAMP is an ongoing clinical trial sponsored by Mindera Corp.) The patient enrollment included patients who would be treated with either anti-IL-17 or anti-IL-23 biologics. RNA samples were collected from patients' skin multiple times before and after treatment to identify molecular biomarkers that could predict patient response to treatment. Baseline samples were collected from all patients.
[0244] After sequencing, RNA-Seq FASTQ files were trimmed using the Trim galore program and then mapped to the human reference genome GRCh38 using the HISAT2 program. The number of reads was counted for each Ensemble gene ID using the FeatureCounts program and humanGRCh38.84.gtf. RNA expression analysis was further processed using the Bioconductor package edgeR. Genes were filtered using filterB yExpr before calculating logCPM (counts per million reads). Plots were created using the ggplot2 and heatmap.2 functions, and functions were compared with standard R functions. The percent of detected genes was calculated using the proportion of detected genes (counts > 0) divided by the total number of Ensemble genes. An overview of the RNA-Seq analysis is summarized in Figure 12.
[0245] Skin biomarker patch platform data This paper discloses a platform that uses skin biomarker patches to extract RNA from skin in a simple, fast and painless manner.Then, next-generation sequencing of the extracted RNA allows to take a snapshot of the genes and transcriptome of skin at the exact moment of this test.Then, this rich patient-specific data set can be analyzed by machine learning algorithms to ask sophisticated questions to this data (for example, predict the appropriate biologic drug for the patient before treatment selection and treatment).
[0246] Lesioned and non-lesioned samples were compared using Mindera patch versus punch biopsy from 66 patients in the Mindera database (Figure 13). The whole transcriptome was analyzed by performing a paired t-test between lesional and non-lesioned skin and then plotting a heatmap for the data with the highest variance (e.g., best P value between groups). Importantly, biomarker data were comparable between Mindera patch and punch biopsy samples. The 30 most differential genes were selected and subjected to unsupervised clustering for visualization, demonstrating excellent differentiation between lesional and non-lesioned skin in the same patient.
[0247] Also disclosed herein is an algorithm for predicting response to biologic (anti-IL-17, anti-IL-23) treatment in patients with psoriasis. A dataset from Tomalin et al. (2020) was used to identify genes whose RNA expression levels correlate with response to treatment with anti-IL-17 biologics in patients with psoriasis.
[0248] In this cohort, 62 responding patients (out of 75) had a PASI change of >0.75, while non-responders had a PASI change of -0.2 to 0.75. The dataset was prefiltered using differentially expressed genes for psoriasis (lesional vs. non-lesional) to minimize the possibility of overfitting. Cross-validation using linear regression modeling showed a balanced predictive accuracy of 0.71 when PASI75 was used as the cutoff for assessing classifier performance. Importantly, a positive predictive value of 0.95 was achieved. Using stepwise AIC (Akaike Information Criteria) linear regression modeling, a total of 17 genes were finalized as correlated with patient response to brodalumab treatment (Table 12). The Akaike information criterion is an estimator of out-of-sample prediction error and, therefore, the relative quality of a statistical model for a given dataset. The Akaike information criterion estimates the relative amount of information lost by a given model; the less information a model loses, the higher its quality.
[0249] [Table 13]
[0250] A heatmap was created from the expression data of these 17 genes (Figure 12). Each column represents a baseline sample collected from a patient. From left to right, patients were categorized by change in PASI from low to high. The blue bars at the top represent 12 non-responders (W12 PASI change <0.75), and the yellow bars represent 62 responders (W12 PASI change >0.75). As shown in the heatmap, the subset of responding patients (far right) had strong downregulation (blue) of most genes, suggesting the potential of using these 17 genes to predict patient response to anti-IL-17 treatment. Downregulation of these 17 genes indicated a better response to treatment, while upregulation indicated a worse response.
[0251] The same analysis was performed prospectively using patients receiving anti-IL-23 biologics. This cohort was derived from patients enrolled in the STAMP trial conducted by Mindera. In this cohort of 17 patients, 5 patients achieved a PASI-75 response by week 12, while 12 patients did not achieve this level of response. Cross-validation using regression modeling demonstrated a balanced predictive accuracy of 0.70 when PASI-75 was used as the cutoff for assessing classifier performance. Importantly, a positive predictive value of 1.00 was achieved. A total of 50 genes were identified as correlated with patient response to anti-IL-23 biologic treatment (Table 13).
[0252] [Table 14-1]
[0253] [Table 14-2]
[0254] Disclosed herein is a platform that utilizes a simple, minimally invasive patch to painlessly collect biomarker samples from patients with psoriasis in minutes. The Mind.Px test has the ability to collect patient data on a large scale, and when combined with high-precision molecular testing, it provides a powerful platform with excellent sensitivity and specificity. The use of this platform, especially when applied to predicting response to expensive treatments, can potentially lead to huge cost savings for the healthcare system, effectively eliminating the trial-and-error approach to treating psoriasis.
[0255] Biomarkers captured using Mind.Px include DNA, RNA, proteins, and small molecules. The role of RNA in chronic skin diseases, in particular, has been well characterized and utilized to provide previously undiscovered predictive associations between patient genetic markers and responsiveness to various drug classes. By capturing RNA from patients' psoriasis lesions, next-generation sequencing was used to evaluate over 7,000 biomarkers per test sample. The results of this biomarker analysis can be used by healthcare providers and payers to predict individual patients' response to certain classes of biologic drugs, depending on the mechanism of action of those drugs, in order to optimize treatment selection. The use of Mind.Px could result in better treatment outcomes and substantial cost savings for the healthcare system.
[0256] Analysis of the classifiers developed in this study demonstrated high positive predictive value in assessing whether a patient will respond to a biologic drug before first exposure. In fact, both classifiers achieved a positive predictive value of >90%, which may significantly impact medical practice and the treatment of psoriasis patients. Interestingly, comparison of the biomarker sets between the algorithms showed some overlap (at least two genes overlap between the anti-IL-17 and anti-IL-23 classifiers).
[0257] Table 14. List of genes that can be used as classifiers to determine the effectiveness of one or more biologics for treating psoriasis. In some embodiments, a method disclosed herein is directed to determining whether a subject with psoriasis will respond positively to an IL-17, IL-23, or TNFα-mediated treatment, and further comprises determining the presence, absence, or expression level of at least 5 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 6 genes selected from Table 14 through 17 genes selected from Table 14. In some embodiments, the method comprises detecting at least 6 genes selected from Table 14 through 7 genes selected from Table 14, 6 genes selected from Table 14 through 8 genes selected from Table 14, 6 genes selected from Table 14 through 9 genes selected from Table 14, 6 genes selected from Table 14 through 10 genes selected from Table 14, 6 genes selected from Table 14 through 11 genes selected from Table 14 through 12 genes selected from Table 14 through 13 genes selected from Table 14 through 14 genes selected from Table 14, 6 genes selected from Table 14 through 14 genes selected from Table 14, 6 genes selected from Table 14 through 15 genes selected from Table 14 through 16 genes selected from Table 14, 17 genes selected from 6 genes selected from Table 14 to 8 genes selected from Table 14, 7 genes selected from Table 14 to 9 genes selected from Table 14 to 10 genes selected from Table 14 to 14, 11 genes selected from Table 14 to 14, 12 genes selected from Table 14 to 14, 13 genes selected from Table 14 to 14, 15 genes selected from Table 14 to 14, 16 genes selected from Table 14 to 14, 17 genes selected from Table 14 to 14,8 genes selected from Table 14 to 9 genes selected from Table 14, 8 genes selected from Table 14 to 14, 10 genes selected from Table 14 to 14, 11 genes selected from Table 14 to 14, 12 genes selected from Table 14 to 14, 13 genes selected from Table 14 to 14, 14 genes selected from Table 14 to 14, 15 genes selected from Table 14 Genes - 16 genes selected from Table 14, 8 genes selected from Table 14 to 17 genes selected from Table 14, 9 genes selected from Table 14 to 10 genes selected from Table 14, 9 genes selected from Table 14 to 11 genes selected from Table 14 to 12 genes selected from Table 14 to 13 genes selected from Table 14 to 14, 9 genes selected from Table 14 to 14, 9 genes selected from Table 14 to 14 15 genes selected from Table 14, 9 genes selected from Table 14 to Table 14, 16 genes selected from Table 14 to Table 14, 17 genes selected from Table 14 to Table 14, 11 genes selected from Table 14 to Table 14, 12 genes selected from Table 14 to Table 14, 13 genes selected from Table 14 to Table 14, 14 genes selected from Table 14 to Table 14, 15 genes selected from Table 14 to Table 14 Genes, 10 genes selected from Table 14 to 16 genes selected from Table 14, 10 genes selected from Table 14 to 17 genes selected from Table 14, 11 genes selected from Table 14 to 12 genes selected from Table 14, 11 genes selected from Table 14 to 13 genes selected from Table 14, 11 genes selected from Table 14 to 14, 11 genes selected from Table 14 to 14, 15 genes selected from Table 14 to 16 genes selected from Table 14,11 genes selected from Table 14 to 17 genes selected from Table 14, 12 genes selected from Table 14 to 13 genes selected from Table 14, 12 genes selected from Table 14 to 14 genes selected from Table 14, 12 genes selected from Table 14 to 14 genes, 12 genes selected from Table 14 to 15 genes selected from Table 14, 12 genes selected from Table 14 to 16 genes selected from Table 14 to 17 genes selected from Table 14, 13 genes selected from Table 14 to 14 genes, 13 genes selected from Table 14 to 15 genes selected from Table 14, 13 genes selected from Table 14 The method further comprises determining the presence, absence, or expression level of 16 genes selected from Table 14, 13 genes selected from Table 14 to 17 genes selected from Table 14, 14 genes selected from Table 14 to 15 genes selected from Table 14, 14 genes selected from Table 14 to 16 genes selected from Table 14, 14 genes selected from Table 14 to 17 genes selected from Table 14, 15 genes selected from Table 14 to 16 genes selected from Table 14, 15 genes selected from Table 14 to 17 genes selected from Table 14, or 16 genes selected from Table 14 to 17 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 6 genes selected from Table 14, 7 genes selected from Table 14, 8 genes selected from Table 14, 9 genes selected from Table 14, 10 genes selected from Table 14, 11 genes selected from Table 14, 12 genes selected from Table 14, 13 genes selected from Table 14, 14 genes selected from Table 14, 15 genes selected from Table 14, 16 genes selected from Table 14, or 17 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 6 genes selected from Table 14, 7 genes selected from Table 14, 8 genes selected from Table 14, 9 genes selected from Table 14, 10 genes selected from Table 14, 11 genes selected from Table 14, 12 genes selected from Table 14, 13 genes selected from Table 14,In some embodiments, the method further comprises determining the presence, absence, or expression level of 14 genes selected from Table 14, 15 genes selected from Table 14, or 16 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of up to 7 genes selected from Table 14, 8 genes selected from Table 14, 9 genes selected from Table 14, 10 genes selected from Table 14, 11 genes selected from Table 14, 12 genes selected from Table 14, 13 genes selected from Table 14, 14 genes selected from Table 14, 15 genes selected from Table 14, 16 genes selected from Table 14, or 17 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 20 genes selected from Table 14 through 50 genes selected from Table 14. In some embodiments, the method comprises the step of detecting at least 20 genes selected from Table 14 through 25 genes selected from Table 14, 20 genes selected from Table 14 through 30 genes selected from Table 14, 20 genes selected from Table 14 through 35 genes selected from Table 14, 20 genes selected from Table 14 through 40 genes selected from Table 14, 20 genes selected from Table 14 through 45 genes selected from Table 14, 20 genes selected from Table 14 through 50 genes selected from Table 14, 25 genes selected from Table 14 through 30 genes selected from Table 14, 25 genes selected from Table 14 through 35 genes selected from Table 14. 35 genes selected from Table 14, 25 genes selected from Table 14 to 40 genes selected from Table 14, 25 genes selected from Table 14 to 45 genes selected from Table 14, 25 genes selected from Table 14 to 50 genes selected from Table 14, 30 genes selected from Table 14 to 35 genes selected from Table 14, 30 genes selected from Table 14 to 40 genes selected from Table 14, 30 genes selected from Table 14 to 45 genes selected from Table 14, 30 genes selected from Table 14 to 50 genes selected from Table 14,In some embodiments, the method further comprises determining the presence, absence, or expression level of 35 genes selected from Table 14 through 45 genes selected from Table 14, 35 genes selected from Table 14 through 50 genes selected from Table 14, 40 genes selected from Table 14 through 45 genes selected from Table 14, 40 genes selected from Table 14 through 50 genes selected from Table 14, or 45 genes selected from Table 14 through 50 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 20 genes selected from Table 14, 25 genes selected from Table 14, 30 genes selected from Table 14, 35 genes selected from Table 14, 40 genes selected from Table 14, 45 genes selected from Table 14, or 50 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of at least 20 genes selected from Table 14, 25 genes selected from Table 14, 30 genes selected from Table 14, 35 genes selected from Table 14, 40 genes selected from Table 14, or 45 genes selected from Table 14. In some embodiments, the method further comprises determining the presence, absence, or expression level of up to 25 genes selected from Table 14, 30 genes selected from Table 14, 35 genes selected from Table 14, 40 genes selected from Table 14, 45 genes selected from Table 14, or 50 genes selected from Table 14.
[0258] [Table 15-1]
[0259] [Table 15-2]
[0260] [Table 15-3]
[0261] Table 15-4
[0262] Table 15-5
[0263] Table 15-6
[0264] Table 15-7
[0265] Table 15-8
[0266] Table 15-9
[0267] Table 15-10
[0268] Table 15-11
[0269] Table 15-12
[0270] Table 15-13
[0271] Table 15-14
[0272] Table 15-15
[0273] Table 15-16
[0274] Table 15-17
[0275] Table 15-18
[0276] Table 15-19
[0277] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the present invention be limited by the specific examples provided within the specification. While the present invention has been described with reference to the foregoing specification, the description and illustration of the embodiments herein are not intended to be construed in a limiting sense. Numerous modifications, changes, and substitutions will occur to those skilled in the art without departing from the invention. Furthermore, it will be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions set forth herein, which depend upon a variety of conditions and variables. It will be appreciated that various alternatives to the embodiments of the present invention described herein may be utilized in practicing the present invention. It is therefore contemplated that the present invention shall cover any such alternatives, modifications, variations, or equivalents. The following claims define the scope of the present invention, and it is intended that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1. A method for determining whether a skin lesion in a subject is responsive to an autoimmune therapeutic agent, comprising: The method is: a. converting RNA in a sample containing RNA derived from the skin collected from the subject into cDNA; b. determining the expression of at least one gene based on said cDNA; c. predicting whether said subject with said skin lesion will respond to said autoimmune therapeutic agent with a positive predictive value of greater than 80%; A method comprising:
2. The method of claim 1, wherein the subject has not been administered the autoimmune therapeutic agent within 7 days prior to obtaining the sample containing the RNA.
3. The method described in claim 1 or 2, which provides a positive predictive value (PPV) of greater than 90%.
4. A method according to any one of claims 1 to 3, wherein the PPV is greater than 95% for a cohort of more than 100 patients.
5. The method of claim 1, wherein the autoimmune therapeutic agent is a biological agent.
6. The method of claim 1, wherein the autoimmune therapeutic agent comprises an antibody.
7. The method of claim 1, wherein the autoimmune therapeutic agent is an IL-17 mediated treatment, an IL-23 mediated treatment, or a TNFα mediated treatment.
8. The method of claim 1, wherein the autoimmune therapeutic agent is an IL-23 mediated treatment.
9. The method of claim 1, wherein the autoimmune therapeutic agent is at least one drug selected from the group consisting of etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab.
10. The method of any one of claims 1 to 9, wherein the autoimmune therapeutic agent is at least one drug selected from the group consisting of certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab.
11. A method according to any one of claims 1 to 10, wherein the at least one gene comprises at least five genes.
12. The method of any one of claims 1 to 11, wherein the at least one gene comprises at least one gene from Table 6, Table 12, or Table 13.
13. The method of any one of claims 1 to 12, wherein the at least one gene comprises at least one gene from Table 13.
14. The method of any one of claims 1 to 13, wherein the autoimmune disorder is psoriasis.
15. The method of claim 1, wherein the subject has a PASI of greater than 8.
16. The method of any one of claims 1 to 15, wherein the subject has a PASI of at least 75 after treatment with the autoimmune therapeutic agent.
17. A method according to any one of claims 1 to 16, wherein the RNA comprises mRNA.
18. The method of claim 1, further comprising a step of performing next-generation sequencing of the cDNA.
19. A method described in any one of claims 1 to 18, further comprising a step of applying a trained algorithm to data generated by next-generation sequencing of the cDNA.
